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ABSTRACT
Temporal lobe epilepsy (TLE) is characterized by hyperexcitability of limbic
structures. The entorhinal cortex (EC) is involved in the initiation and maintenance of
TLE. Layers II and III of the EC in particular are hyperexcitable and are more susceptible
to epileptogenesis. TLE is influenced in a complex manner by the stress-released
epileptogenic neuropeptide, corticotropin-releasing factor or hormone (CRF/CRH).
Nevertheless, the action site and underlying mechanisms of CRF in epilepsy are not fully
understood. Here we found that the EC expresses high levels of CRF and CRF 2 receptors
R

R

without the expression of CRF 1 receptors. CRF increased the frequency of picrotoxin
R

R

(PTX)-induced epileptiform activity via CRF 2 receptors and requires cyclic AMP
R

R

(cAMP). However, application of selective protein kinase A (PKA) inhibitors reduced,
not completely blocked CRF-induced enhancement of epileptiform activity suggesting
that PKA is only partially required. Furthermore, endogenously released CRF is also
involved in the epileptogenesis.
Among various ionic conductances maintaining neuronal excitability, the
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and the conducting
current I h has strongly been implicated in TLE. Whereas, layer III of the EC shows
R

R

preferential neuronal loss in TLE, layer II is spared and becomes hyperexcitable. Since
the stellate neurons of layer II express high levels of HCN channels, we investigated the
role of HCN channels in CRF- mediated facilitation of epileptiform activity. In the
xv

presence of HCN-channel blocker-ZD7288, CRF failed to increase the frequency of
epileptiform activity but still augmented the numbers of synchronizing events within an
epileptiform activity and the duration of epileptiform activity. This suggests that part of
the effects of CRF on epilepsy is mediated via HCN channels. Furthermore, using
perforated patch clamp recordings we found that CRF increased I h recorded from layer II
R

R

stellate neurons via activation of CRF 2 receptors. cAMP, not PKA was responsible for
R

R

CRF-mediated facilitation of I h . At the cellular level, CRF depolarized the membrane
R

R

potential resulting in increase in neuronal excitability and action potential firing. These
mechanisms facilitate an increase in epileptiform activity mediated by CRF, in the EC.
Our results provide a novel cellular and molecular mechanism whereby CRF modulates
epilepsy.

xvi

CHAPTER I
INTRODUCTION
Epilepsy
Epilepsy is defined as “a disorder of the brain characterized by an enduring
predisposition to generate epileptic seizures and by the neurobiologic, cognitive,
psychological, and social consequences of this condition” (International League Against
Epilepsy (ILAE) (Fisher et al., 2005b). Seizures are complex manifestation of transient,
abnormal and synchronous enhancement of neuronal excitability in response to adverse
internal and external variables with different and distinct effects (Fisher et al., 2005a,
0T

0T

Engel et al., 2006). Epilepsy is a chronic neurological disorder characterized by two or
more unprovoked seizures (Duncan et al., 2006). Epileptogenesis is the sequence of
events in which a normal brain transforms into a hyperexcitable epileptic neuronal
circuit. Epilepsy is the third most common, multifarious and devastating neurological
disorder affecting 50 million people worldwide (Hauser and Kurland, 1975, Hirtz et al.,
2007, Kobau et al., 2008) and more than two million people. Epilepsy usually presents in
childhood and people over 65 years age, but may occur for the first time at any age
(Hauser et al., 1993, Olafsson et al., 2005). Five percent of the population suffer a single
seizure at some time in their life.

1

Etiology of Epilepsy
Etiology is an important determinant of treatment, prognosis, and clinical course.
Based on the etiology, the ILAE Commission divided epilepsies into three distinct
categories (Berg et al., 2010). a. Genetic epilepsies in which seizures are the core
symptom of a disorder due to a known or presumed genetic defect(s) (Berg et al., 2010).
b. Structural or metabolic epilepsies which are the result of structural or metabolic
condition, including acquired disorders and genetic conditions, in which there is a
separate condition between the genetic defect and the epilepsy (Berg et al., 2010).
c. Epilepsy of an unknown etiology, also referred to as idiopathic epilepsy, accounts for
70% of epilepsies where the cause is not currently known, but may be of genetic origin or
the result of a separate, unrecognized disorder (Hauser et al., 1991, Duncan et al., 2006,
Berg et al., 2010).
Seizure Classification
Based on the seizure semiology and electroencephalography (EEG), ILAE
(Gastaut, 1969, Epilepsy, 1981, 1989, Luders et al., 1993, Engel, 2001) classified
epileptic seizures into: 1. Partial or focal seizures, in which the abnormal electrical
discharge originates from a localised epileptic focus. Partial seizures can be further
subdivided into: a. simple partial seizures are the most common type of epilepsy and do
not affect consciousness. b. Complex partial seizures affect consciousness. In adults,
partial seizures are most the most common form accounting for 60 – 70 % of all seizures
(Hauser et al., 1993, Forsgren et al., 1996, Oun et al., 2003).2. Generalized seizures
involve many parts of the brain. Generalized seizures can be further subdivided into:
2

a. Absence seizures (petit mal) which typically occur in childhood. These seizures are
distinguishable by brief lapses of consciousness lasting less than 30 seconds such as
staring, blinking, rolling of the eyes, or arm movements, followed by full awareness.
b. Myoclonic seizures which are rapid, shock-like jerks of a muscle or group of muscles.
c. Clonic seizures which occur when several myoclonic seizures occur in succession.
d. Tonic seizures which cause muscle stiffening, usually in back, legs and arms. e. Tonicclonic seizures (grand mal) which are characterized by a stiffening of body (tonic phase)
and jerking movements (clonic phase). A person sometimes loses consciousness during a
tonic-clonic seizure and may also have shallow breathing and a loss of bowel/bladder
control. They are the most common form of generalized seizures. f. Atonic seizures
which cause an abrupt loss of normal muscle tone for seconds resulting in head nods, jaw
drops or even falls. Partial seizures may spread to other parts of the brain and transform
to generalized seizures. 3. Unknown seizures such as epileptic spasms and the events that
are not clearly diagnosed into one of the categories above. Generalized and partial
seizures occasionally may lead to continuous or recurrent seizures lasting longer than 30
minutes without full recovery of consciousness. Continuous generalized seizures, known
as status epilepticus is a life-threatening condition and requires an immediate
pharmacological treatment. Continuous partial seizure activity, epilepsia partialis
continua, though less life threatening, if left untreated for prolonged conditions results in
focal neuronal damage and generalize into status epilepticus.

3

Figure 1.

ILAE classification of seizures. (Adopted from: Epilepsy.org.au)
Epileptic and Non-Epileptic Events

Electroencephalography (EEG) recordings in epileptic patients show sharp wave,
spike, spike-and-slow wave complex and the multiple spike-and-slow-wave complex
patterns which are referred to as epileptiform activity. Subclinical or interictal discharges
are often observed between seizures which also exhibit the patterns of epileptiform
activity. However, it must be noted that not all seizures are epileptic. For example,
medical conditions such as narcolepsy, heat stroke, cardiac arrhythmia and low blood
4

sugar have symptoms similar to epileptic seizures, but show no abnormal electrical
activity (Hauser et al., 1996). Non-epileptic events can occur in both epileptic and nonepileptic patients.
Treatment Strategies
Current treatment strategies for seizures focus exclusively on prophylaxis or
seizure suppression, thus providing only a symptomatic treatment (Rogawski and
Loscher, 2004) without clear influence on the cause of disease and produce various side
effects (Pitkanen and Sutula, 2002). Anti-epileptic drugs (AEDs) are the most commonly
used treatment strategy for epilepsy. AEDs are designed to restore the normal balance
between excitation and inhibition of the neuronal network (Avoli, 1983, Mody et al.,
1992). AEDs target a number of mechanisms such as: increase the inhibitory
neurotransmission via gamma-aminobutyric acid (GABA), decrease the excitatory
glutamatergic transmission, and reduce neuronal excitability by modulation of sodium or
calcium channels (Figure 2). However, a substantial proportion of patients (~30%) do not
respond to AEDs (Perucca et al., 2007) and continue to have seizures despite carefully
optimized drug treatment (Regesta and Tanganelli, 1999). In patients with intractable
epilepsy, other treatments may be needed. In some cases, a ketogenic diet rich in fatty
acids and free from carbohydrates or a vagus nerve stimulator has been proven to be
helpful. However, the effects have not always been promising (Danielsson et al., 2008).
Removal of epileptic tissue can be a cure for a select population with clear epileptogenic
focus. In some cases of febrile seizures, corticosteroid treatment is often preferred.

5

However, there is no easy cure or prophylactic regimen. Intractability to currently
available anticonvulsants may indicate multiple mechanisms of seizure generation.Hence,
even when one mechanism is targeted, the others still can exacerbate the disease.

Adopted from (Bialer and White, 2010, Loscher and Schmidt, 2012)
Figure 2.

Clinically approved AEDs with a wide spectrum of mechanisms of action.
Effects on both inhibitory (left-hand side) and excitatory (right-hand side)
nerve terminals.
(AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid;
GABA, γ-aminobutyric acid; GAT-1, sodium- and chloride-dependent
GABA transporter 1; SV2A, synaptic vesicle glycoprotein 2A).

Therefore, advances in the knowledge of the underlying mechanisms of epilepsies would
allow for more rational therapeutic approaches to this challenging neurological disorder
6

(Perucca et al., 2007). Temporal lobe epilepsy (TLE) is one of the most prevalent
intractable epilepsies in adults, and the cellular and molecular basis for the
pharmacoresistance of the epilepsy has so far remained elusive (Engel, 1996).
TLE
TLE manifests as a partial seizure (Kwan and Brodie, 2000). There are many
causes of TLE such as brain injuries, brain tumors, vascular malformations and
developmental abnormalities. TLE can be mesial TLE (MTLE) or lateral TLE. The
MTLE or limbic epilepsy is the most common form of TLE (Wiebe, 2000) and involves
the interaction among neuronal networks in limbic structures such as the hippocampus,
amygdala and the entorhinal cortex (EC) (Engel, 1993). The LTLE is the less common
form of TLE and arises in the neocortex. In about 60% of TLE patients, seizures spread
from temporal lobe to the adjacent occipital, frontal, parietal as well as to the temporal
lobe on the contralateral side of the brain. This process is called secondary generalization.
The result is a convulsive (grand mal) seizure. Whereas some of the TLE patients
develop abnormal tissue damage such as the mesial temporal sclerosis, which is
amenable to resection, the number of options is limited for those without such lesions.
Therefore, unraveling additional mechanisms would allow new targets for future therapy
developments not only for patients with non-surgical intractable epilepsy, but also for
other types of epilepsies.
TLE and the EC
In patients with intractable seizures, seizure onset is frequently detected in the
hippocampus. However, human and animal studies provide increasing evidence that other
7

structures of the limbic system, such as the amygdala, parts of neocortex, and the EC also
play important roles. In line with these studies, the EC has been implicated in the
development and propagation of limbic seizures in TLE patients (Rutecki et al., 1989,
Spencer and Spencer, 1994, Bartolomei et al., 2001) and in animal models mimicking
this disorder (Dreier and Heinemann, 1991, Bragdon et al., 1992, Jones et al., 1992,
Heinemann et al., 1993, Avoli et al., 1996). However, the processes leading to
spontaneous seizures involving the EC have not been fully determined.
Structure of the EC
Anatomically, the EC is a six-layered pivotal structure (layers I-VI, Figure 2)
10T

10T

(Mulders et al., 1997) integrating information from the parahippocampus, prefrontal
cortex, and the frontal cortex (Apergis-Schoute et al., 2006). Hence the EC is considered
the gateway mediating the majority of connections between the hippocampus and other
cortical areas (Witter et al., 1989, Witter et al., 2000a, Witter et al., 2000b). Layer I is the
molecular layer, which has a scarcity of cells, whereas layer IV is the cell-sparse, fiberrich narrow layer that constitutes the lamina dissecans. Layer II is mainly made up of
densely packed, large and medium sized pyramidal and stellate cells. The most abundant
cell type throughout layer II in medial EC (mEC) is the stellate cells, located within the
superficial and middle layer II. The soma of these cells is quite variable but their spiny
dendritic tree is their defining characteristic. Layer III consists of a high density of
pyramidal neurons (Dickson et al., 1997, Gloveli et al., 1997). Sensory inputs from
olfactory structures, parasubiculum, perirhinal cortex, claustrum, amygdala and neurons
in the deep layers of the EC (layers V–VI) converge onto the superficial layers (layer
8

II/III) of the EC (Witter et al., 1989, Burwell, 2000) which give rise to dense projections
to the hippocampus. The axons of the stellate neurons in layer II of the EC form the
perforant path that innervates the dentate gyrus and Cornu Ammonis (Steward and
Scoville, 1976), whereas those of the pyramidal neurons in layer III form the
temporoammonic pathway that synapses onto the distal dendrites of pyramidal neurons in
CA1 and the subiculum (Steward and Scoville, 1976, Witter et al., 2000a, Witter et al.,
2000b). Furthermore, neurons in the deep layers of the EC (layers V–VI) relay a large
portion of hippocampal output projections back to the superficial layers of the EC
(Kohler, 1986, Dolorfo and Amaral, 1998a, b, van Haeften et al., 2003) and to other
cortical areas (Witter et al., 1989). Accordingly, the EC is not only involved in the
induction and maintenance of TLE (Spencer and Spencer, 1994, Avoli et al., 2002), but
also closely involved in the consolidation and recall of memories (Haist et al., 2001,
Squire et al., 2004, Dolcos et al., 2005, Steffenach et al., 2005), Alzheimer's disease
(Hyman et al., 1984, Kotzbauer et al., 2001), and schizophrenia (Falkai et al., 1988,
Arnold et al., 1991, Joyal et al., 2002, Prasad et al., 2004).
Role of the EC in TLE
Clinical and animal studies show that the EC is a site of seizure initiation and
maintenance. The EC is also involved in acutely induced epileptiform discharges
(Walther et al., 1986, Wilson et al., 1988, Jones and Lambert, 1990, Pare et al., 1992,
Stringer and Lothman, 1992, Bear and Lothman, 1993, Rafiq et al., 1993). Preferential
loss of layer III neurons of the EC is seen in both human TLE (Kim et al., 1990, Du et al.,
1993) as well as animal models of epilepsy (Du and Schwarcz, 1992, Du et al., 1995).
9

With the onset of epilepsy, CA3 neurons are lost and the Schaffer collateral (SC)
pathway connecting CA3 to the CA1 pyramidal neurons is disrupted (Ben-Ari and
Cossart, 2000). Under these conditions, the TA pathway has been suggested as a major

(Adopted and modified from © 2012 Neural Circuits and Memory Lab).
Figure 3.

EC forms the gateway to the hippocampus and other cortical areas.
Superficial layers (II, III) send sensory inputs to the hippocampus.
Stellate neurons in layer II form Perforant path with DG cells and CA3
Pyramidal neurons in layer III form Temporoammonic pathway
connecting CA1 and subiculum
CA1 sends it output to layers V/VI of the EC which in turn relay back to
the superficial layers.

excitatory drive to the principal neurons of the CA1 region (Barbarosie et al., 2000, Avoli
et al., 2002, Wu and Leung, 2003). The neurons of layer II are well spared in TLE.
However, they become hyperexcitable (Bear et al., 1996) due in part to a reduction in
inhibitory input (Kobayashi and Buckmaster, 2003), and proexcitatory alterations in
sodium channel gating parameters (Hargus et al., 2011). Additionally, removal of the
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parahippocampal gyrus along with the EC, showed better seizure management in patients
with refractory epilepsy (Siegel et al., 1990, Engel, 1993).
Auras and Seizure Precipitation Factors
In some cases, epileptic seizure can be predicted. Auras are symptoms that occur
in some epileptic patients before the onset of a seizure. These include a strange taste or
odor or sounds, feeling of numbness or tingling, anxiety and nausea. Whereas in some
epileptic patients, seizures are triggered (Berg et al., 1995). Triggering factors can be
environmental or endogenous in origin and cause a transient lowering of the seizure
threshold, or chemical or physiological stimulation capable of precipitating an ictal event
(Aird, 1983, Nakken et al., 2005). In most cases, multiple factors are involved in setting
off seizures and are rarely predictable. However, in some cases it is possible to determine
what triggers the onset of seizures. In addition to determining the underlying causes of a
seizure disorder, identifying and managing factors that precipitate seizures can aid in
developing behavioral or lifestyle changes that can improve seizure control and the
patient’s need for medication. Some known potential precipitants that often encourage
seizures include: alcohol consumption, alcohol withdrawal, various medical conditions
such as multiple sclerosis, fever, photosensitivity, drugs, sleep deprivation, anxiety and
stress.
Stress and Epilepsy
Stress is the more frequently self-reported precipitant of seizures in patients with
refractory epilepsy (Frucht et al., 2000, Spector et al., 2000, Nakken et al., 2005, Haut et
al., 2007, Sperling et al., 2008). Stress can be internal or environmental signals perceived
11

as a potential threat (Behan et al., 1995b, Cortright et al., 1995, Hsu and Hsueh, 2001,
Calabrese et al., 2007). Although stress does not cause epilepsy, it can make a person
more prone to seizures. Additionally, getting anxious about having seizures can add to
stress and thus forms a vicious cycle of seizures and stress. In support of these clinical
studies, stress pathways have been shown to promote neural activity in a variety of ways,
suggesting its direct contribution to hyperexcitability resulting in spontaneous seizures.
The mammalian brain is equipped with numerous sensing devices to identify stress, as
well as mechanisms to respond to the stress signals (Behan et al., 1995b, McEwen, 2011).
Mild or acute stress is often adaptive as it enhances functions of the hippocampus and
other brain regions by augmenting synaptic plasticity, to cope with the situation if it ever
occurs again (Behan et al., 1995b, Cortright et al., 1995, Joels et al., 2011). However, the
same mechanisms when chronically activated render the brain more susceptible to
numerous detrimental effects (Cortright et al., 1995, Joels et al., 2007, Joels et al., 2011),
including seizure precipitation.
Stress Mechanisms Activate the Excitatory Neuropeptide CRF
How does the brain detect and reacts to a stressful stimulus and trigger seizures?
When an individual appraises a situation as a threat, stress responses get activated
(Lazarus and Folkman, 1984). Two major components are principally engaged to adopt to
stress challenges; i) the sympathetic-adrenomedullary system is activated for rapid- and
short-lived responses and results in increased systemic levels of norepinephrine and
epinephrine, and increased levels of norepinephrine in the brain. ii) The hypothalamicpituitary-adrenal (HPA) system is activated for delayed, sustained responses and involves
12

various hormones and neuropeptides (Behan et al., 1995b, Cortright et al., 1995, De
Kloet et al., 1998, Calabrese et al., 2007) (for a detailed review, see (Turnbull and Rivier,
1997)). Activation of the HPA axis involves the limbic system in the brain, which is
composed of the amygdala, prefrontal cortex and the hippocampus (Figure 3). The
amygdala creates an emotional response in reaction to stress, while the hippocampus
creates a memory of the threat to deal with it in a better way in future. Stressful or
threatening stimuli pass through the amygdala and reach the paraventricular nucleus
(PVN) of the hypothalamus via neurochemical pathways. The PVN then releases
corticotropin releasing factor (CRF) into the adenohypophyseal portal circulation
(Whitnall, 1993). CRF activates CRF receptors on anterior pituitary corticotrophs
resulting in the release of adrenocorticotrophin hormone (ACTH) (Turnbull and Rivier,
1997). ACTH then signals the pituitary gland to stimulate adrenal glands to release
cortisol (corticosterone in rodents) (Vale et al., 1981) Cortisol and other glucocorticoids
released from the adrenal cortex, help to mobilize resources for sustained actions. These
include changes such as increased blood glucose and lipid levels, increased heart rate,
blood pressure as well as immune responses involving circulating T cells, B cells and
lymphocytes. In the short term, these resources are useful in helping the body to deal with
stressors. However, chronic activation of these mechanisms may contribute more to the
development of various diseases.
Overview of the CRF System
CRF is known as the most potent epileptogenic neuropeptide. Therefore,
appreciation of the circuitry affected by the CRF-system is particularly germane to
13

understand the effects of CRF on seizure threshold, seizure susceptibility and
epileptogenesis. CRF plays a fundamental role in responding to stressors exposed to the
human body (Hemley et al., 2007) and mediates both short and long term responses to
stress.

Figure 4.

Schematic illustration of the HPA axis signaling.
Stress signals stimulate CRF neurosecretory cells in PVN of the
hypothalamus to release CRF.
CRF then activates ACTH secretion from corticotrophs of anterior
pituitary gland.
ACTH travels to adrenal glands of kidneys and stimulates release of
cortisol.
To protect against prolonged activity as well as help regain homeostasis,
the HPA system is carefully modulated through negative feedback exerted
by cortisol at anterior pituitary, PVN and the hippocampus.
- : Inhibition, + : Activation.
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Dysregulation of the CRF–system has been implicated in a myriad of “stress-related”
disorders, including epilepsy (Baram and Hatalski, 1998, Hauger et al., 2006).
CRF is known to change neuronal function in a rapid and reversible manner. CRF
is an excitatory neuromodulator (Dunn and Berridge, 1990). There are numerous CRF
pathways outside the HPA axis (Lymangrover and Brodish, 1973) where CRF acts as
central neuromodulator (Swanson et al., 1983). The CRF signaling system comprises of 4
CRF family ligands, a binding protein, and two receptors (Vale et al., 1981, Behan et al.,
1995a, Steckler and Holsboer, 1999, Ryabinin et al., 2002, Fekete and Zorrilla, 2007).
CRF family ligands. CRF, urocortins (Ucn 1 , Ucn 2 or stresscopin-related peptide,
R

R

R

R

and Ucn 3 or stresscopin), urotensins (UTn 1 , UTn 2, and UTn 3 ), and sauvagine (Svg) are
R

R

R

R

R

R

R

R

R

R

the four ligands that belong to the CRF family.
CRF gene location and homology. CRF is found in all vertebrates (Batten et al.,
1990, Bhargava and Rao, 1993) and mammals (Paull et al., 1982, Sakanaka et al., 1986,
Stolp et al., 1987) including primates (Millan et al., 1986) and humans (Chan et al., 1982,
Binder and Nemeroff, 2009). The CRF gene contains two exons separated by an intron
that is around ~600–800 base-pair long (Furutani et al., 1983, Shibahara et al., 1983,
Jingami et al., 1985, Roche et al., 1988, Morley et al., 1991, Stenzel-Poore et al., 1992b,
Keegan et al., 1994, Mimmack et al., 1998) and is located on chromosome 8q13. The first
exon contains mostly untranslated mRNA, while the second exon encodes the entire
translated region of CRF precursor. Although CRF mRNAs differ in length in all these
species, the CRF gene is highly conserved and the same gene sequence is found in almost
all animals (De Souza et al. 2000). Human CRF is identical to that of rat and differs from
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ovine by only seven amino acids. This homology of the CRF gene has been exploited to
learn more about human CRF as well as to develop antagonists, using CRF from other
species (Hemley et al., 2007).
CRF structure. CRF is a 41 amino acid polypeptide (Vale et al., 1981), cleaved
from the pro-peptide at dibasic amino acids (lysine or arginine residues) (Shibahara et al.,
1983, Roche et al., 1988, Morley et al., 1991, Stenzel-Poore et al., 1992b). The glycine
residue in the C-terminal, Gly-Lys serves as a template for amidation. The 3D- structure
of the peptide is not fully discovered. However, it is believed that CRF is made up of a
defined alpha helix with an unstructured terminal end at each side, which may also form a
helix when bound to a receptor. This double helical confirmation might possibly be the
biologically active form of CRF (Grigoriadis et al. 2001). CRF is released at synaptic
terminals upon depolarization (Smith et al. 1986) and is characterized by saturable,
reversible, specific binding to its receptors (De souza et al, 1985).
CRF Distribution. CRF is ubiquitous in the mammalian central nervous system
(CNS) (Swanson et al., 1983, Dautzenberg and Hauger, 2002). Apart from the PVN and
lateral area of the hypothalamus, CRF immunoreactivity has been detected in various
extra-hypothalamic regions such as cerebellar cortex (Cha and Foote, 1988, Arzt and
Holsboer, 2006), locus coeruleus (Cha and Foote, 1988), olfactory bulb (Bassett et al.,
1992) and limbic structures including the EC (Bassett et al., 1992, Park et al., 2003),
amygdala (Bassett and Foote, 1992) and the hippocampus (Yan et al., 1998, Park et al.,
2003). The distribution of CRF neurons in the brain is consistent with its role in
endocrine, physiological and behavioral responses to stress. The identity of the CRF16

containing neurons can be either GABAergic (Primus et al., 1997, Yan et al., 1998) or
glutamatergic (Cain et al., 1991, Valentino et al., 2001).
Regulation of CRF Expression. Stress adaptation involves either down-or upregulation of CRF expression, depending on the brain regions. CRF gene transcription
site involves the promoter and 5′-upstream region containing glucocorticoid response

Adopted from: Holmes, A. et al., Trends Pharmacol Sci 24 (11), 580 (2003)

Figure 5.

Distribution of CRF mRNA.
CRF-like immunoreactivity is seen in regions including the hypothalamus,
amygdala, BNST and cortex.
0T

element (GRE) and cyclic AMP (cAMP) response elements (CRE), and Pit-1, Oct-1,
Oct-2 and Caenorhabditis elegans Unc86(POU) transcription factor binding sites (Roche
et al., 1988, Xu et al., 2001, Parham et al., 2004). In rodents, exogenous central CRF
administration generates a large increase in CRF mRNA expression in the PVN (Parkes
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et al., 1993). This finding is consistent with studies in which acute or chronic stress
significantly increases endogenous CRF mRNA expression in hypothalamic PVN and the
central nucleus of amygdala (Ma et al., 1999, Makino et al., 1999, Figueiredo et al., 2003,
Shepard et al., 2005). Additionally, increases in CRF mRNA induced by acute stress are
mediated via CRE-binding protein (CREB) phosphorylation by protein kinase A (PKA)
(Itoi et al., 1996, Kovacs and Sawchenko, 1996). While acute stress initially triggers a
rapid increase in CRF mRNA in rat PVN, chronic stress results in an increase in
inducible cAMP early repressor (ICER) mRNA expression, thus preventing cAMPdependent CRF gene transcription (Shepard et al., 2005). Failure of this regulatory
mechanism could therefore be one of the major contributors for CRF hypersecretion.
Regulation of CRF release. In addition to the gene transcription mediated
control, CRF release is regulated by a number of other factors such as angiotensin,
vasopressin, neuropeptide-Y, substance P, atrial natriuretic peptide, activin, melanin
concentrating hormone, β-endorphin, and possibly CRF itself. Whereas neurotransmitters
such as acetylcholine, norepinephrine, histamine and serotonin promote CRF release,
GABA inhibits the release of CRF. In addition, cytokines such as interleukin-1β, tumor
necrosis factor, eicosanoids, and platelet-activating factor have been shown to activate
the HPA-axis by increasing hypothalamic CRF expression.
CRF Receptors. CRF transduces neuronal and endocrine signals by binding to
two G-protein coupled receptor types, CRF receptor 1 (CRF 1 ; also known as CRFR1and
R

R

R

R

CRHR1) and CRF receptor 2 (CRF 2 ; also known as CRFR2 and CRHR2) (Perrin et al.,
R

R

1993, Lovenberg et al., 1995b, Dautzenberg and Hauger, 2002). CRF receptors are
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component of seven transmembrane α-helical proteins that belong to class II or B
receptor superfamily.. Human CRF 1 and CRF 2 receptor genes are mapped to
R

R

R

R

chromosomes 17q21 and 7p14, respectively (Polymeropoulos et al., 1995, Meyer et al.,
1997). CRF-mediated signal transduction is triggered when CRF-type ligand binds to the
interior of the helical protein core (Perrin and Vale, 1999, Hillhouse and
Grammatopoulos, 2006) (De Souza, 1995, Dautzenberg and Hauger, 2002, Chatzaki et
al., 2006, Fekete and Zorrilla, 2007). Distinct genes encode for CRF 1 and CRF 2 receptors,
R

R

R

R

while retaining a 70% peptide sequence homology in all species. Post translational
splicing results in isoforms with variants having altered intercellular or transmembrane
domains (Lovenberg et al., 1995a, Zmijewski and Slominski, 2010). CRF receptors are
highly conserved and are present in a wide variety of vertebrates, including but not
limited to mouse (Vita et al., 1993, Kishimoto et al., 1995, Perrin et al., 1995a, Stenzel et
al., 1995), rat (Chang et al., 1993, Perrin et al., 1993, Lovenberg et al., 1995a) and
humans (Chen et al., 1993, Vita et al., 1993). CRF 1 and CRF 2 display distinct
R

R

R

R

pharmacological profiles (De Souza, 1995, Dautzenberg and Hauger, 2002, Chatzaki et
al., 2006, Fekete and Zorrilla, 2007) and are widely distributed in the extrahypothalamic
circuits; with some splice variants located in specific peripheral tissues (Potter et al.,
1994, Chalmers et al., 1995, Hiroi et al., 2001). Recently, a third CRF receptor subtype
termed CRF 3 was cloned from catfish, which is highly homologous to CRF 1 receptor.
R

R

R

R

However, no such subtype has been reported to date in humans (Arai et al., 2001).
CRF 1 receptors. CRF 1 was cloned from several species, including human,
R

R

R

R

mouse, rat (Chen et al., 1993, Dieterich et al., 1997) and has no known functional genetic
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polymorphism. CRF 1 is the primary endocrine transduction pathway of CRF, and is
R

R

found at high densities in the anterior pituitary. In the brain, CRF 1 are expressed mainly
R

R

in the medial septum, pituitary, cerebral cortex, cerebellum, hippocampus, amygdala,
raphe nuclei, hindbrain, and olfactory bulb (De Souza et al., 1985, Chang et al., 1993,
Primus et al., 1997, Rominger et al., 1998, Hauger et al., 2006). Peripheral CRF 1
R

R

receptors are located in adrenal gland, ovaries, testes and skin. The mRNA distribution
for CRF 1 correlates well with the known distribution of CRF binding sites (Bittencourt
R

R

and Sawchenko, 2000b). When expressed in cells, CRF 1 exhibits an identical in vitro
R

R

pharmacological profile similar to that in brain and pituitary. Based on these
observations, several novel CRF receptor-antagonist molecules were developed to probe
the physiological significance of this receptor (McCarthy et al., 1999). CRF binds with
high affinity to CRF 1 (Perrin and Vale, 1999, Hauger et al., 2003). Urocortins (Ucn),
R

R

urotensins, and sauvagine also bind to CRF receptors. Among the urocortins, Ucn1 binds
to CRF 1 receptors with affinity similar to CRF. Both CRF and Ucn1 can therefore be
R

R

considered as endogenous ligands for CRF 1 (Hauger et al., 2003).
R

R

CRF 2 receptors. CRF 2 receptors are known to exist in 4 isoforms: CRF 2 α,
R

R

R

R

R

R

CRFR 2 α-tr, CRF 2 β, and CRF 2 δ. CRF 2 α is a 411 amino acid protein and is about 71%
R

R

R

R

R

R

R

R

identical to CRF 1 (Lovenberg et al., 1995b). CRF 2 α is localized to subcortical regions,
R

R

R

R

including lateral septum, paraventricular, ventromedial nuclei of the hypothalamus and
the EC (Lovenberg et al., 1995a). CRF 2 α-tr is a novel short variant of 2α-isoform cloned
R

R

from the rat amygdala (Miyata et al., 1999). CRF 2 α-tr exhibits differential brain
R

R

expression and is pharmacologically related to CRF 2 α. CRF 2 β is a 431 amino acid
R
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R

R

R

protein and differs from CRF 2 α in that the first 34 amino acids in the N-terminal
R

R

extracellular domain are replaced by 54 different amino acids (Perrin et al., 1995b).
CRF 2 β is localized primarily to heart, skeletal muscle, cerebral arterioles and choroid
R

R

plexus (Chalmers et al., 1995). CRF 2 δ in human brain (Kostich et al., 1998) is expressed
R

R

in amygdala and the hippocampus, whereas no such subtype exists in rat. The binding
affinity of CRF to CRF 2 is 15 times lower than that of CRF 1 (Perrin and Vale, 1999,
R

R

R

R

Hauger et al., 2003). CRF-like peptides UTn1, sauvagine, generally binds to CRF 2 . More
R

R

importantly, Ucn2 and Ucn3 have nearly 100 times greater affinity to CRF 2 than CRF
R

R

(Hauger et al., 2003), and show little or no effect on CRF 1 . Thus Ucn is hypothesized as
R

R

the endogenous ligand for CRF 2 (Vaughan et al., 1995).
R

R

CRF-binding protein. CRF levels are maintained by a soluble 322 amino acid,
37 kDa glycoprotein, known as CRF-binding protein (CRF-BP). CRF-BP buffers the
amount of free CRF in extracellular compartment (Jahn et al., 2005), both in periphery
and in the brain. CRF-BP was ﬁrst inferred from studies in pregnant humans and was
thought to block the effects of CRF, to attenuate activation of the HPA axis. Later,
studies established that CRF-BP is highly expressed in brain, plasma, heart, lungs,
intestines, and placenta (Potter et al., 1992, Boorse and Denver, 2006, Vitoratos et al.,
2006). In rats, CRF-BP expression is restricted to the brain. Immunohistochemistry and
in situ hybridization studies reveal that CRF-BP is expressed in various areas of rat brain
including cerebral cortex, amygdala, hippocampus, and sensory relay nuclei associated
with auditory, olfactory, vestibular, and trigeminal systems (Potter et al., 1992). Thus, the
differential distribution of brain CRF-BP and CRF receptors presents multiple distinct
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sites of interaction with CRF (Behan et al., 1993a). CRF-BP is possibly involved in the
brain maintenance of the synaptic CRF concentrations either by presynaptic uptake or by
modulating the quantity of neuropeptide that activates CRF receptors at the membrane
interface (Turnbull and Rivier, 1997).
In the periphery, CRF-BP binds to CRF and dimerizes to prevent CRF-binding
receptor bioavailability (Behan et al., 1995a). In the brain, CRF-BP is membraneassociated (Behan et al., 1995). The interaction between CRF and CRF-BP is possibly
due to maintenance of synaptic CRF concentrations either by presynaptic uptake or
modulation of neuropeptide availability that activates CRF receptors (Turnbull and
Rivier, 1997). The role of CRF-BP is not completely understood. However, the
differential distribution of CRF-BP shows that the protein has much broader potential for
buffering, inhibiting, or enhancing the effects of CRF family of peptides binding to its
receptors. Furthermore, the type of effect depends on localization and concentration
(Seasholtz et al., 2002), similar to the receptors. CRF-BP binds CRF and urocortins
(except Ucn 3 ) with affinity similar to or greater than CRF receptors, and inhibits CRFR

R

induced ACTH releasing properties of CRF receptor agonist in vitro in a dose-dependent
fashion (Lowry et al., 1996).
CRF-mediated second messenger signaling. Both CRF 1 and CRF 2 are primarily
R

R

R

R

coupled to G s proteins resulting in activation of adenylyl cyclase (AC) and increase in
R

R

levels of cAMP, which activates PKA (Dautzenberg and Hauger, 2002, Grammatopoulos
and Chrousos, 2002, Hauger et al., 2006). CRF receptors also have various degrees of
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CRF1

CRF2
Adopted from (Kuperman and Chen, 2008)

Figure 6.

Schematic representation of the mammalian CRF–urocortin family of
peptides, receptors and binding proteins.(Kuperman and Chen, 2008).
Colored arrows indicate the receptors and binding proteins with which
each ligand interacts.
Dotted arrow indicates relatively lower affinity, as compared with
unbroken arrow.
CRF has relatively lower affinity for CRF 2 compared with its affinity for
CRF 1 . Ucn1 has approximately equal affinity for both receptors; Ucn2 and
Ucn 3 are selective for CRF 2 .
The signaling cascade also includes CRF-BP and the recently identified
sCRF 2a . Both CRF-BP and sCRF 2a bind to CRF and urocortin 1 with high
affinity.
R

R

R

R

R

R

R

R

R

R

coupling competence and potency to interact with other G-protein systems including G q ,
R

R

G i , G o , G i1/2 , and G z (Grammatopoulos et al., 2001). Thus CRF can modulate various
R

R

R

R

R

R

R

R

signaling cascades and kinases comprising of protein kinase B (PKB), protein kinase C
(PKC), mitogen-activated protein (MAP) kinases and intracellular Ca2+ concentrations in
P

P

a tissue-specific and concentration dependent manner (Dautzenberg and Hauger, 2002,
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Grammatopoulos and Chrousos, 2002, Hauger et al., 2006). The biological actions of
CRF are likely to be mediated by these CRF receptors and their intracellular signals.
CRF/receptor complex internalization and sensitivity. Following CRF receptor
binding, G-proteins are phosphorylated and the α-subunits are dissociate from βγ to
stimulate second messenger cascades. CRF receptors are then rapidly desensitized by Gprotein related kinases (GRKs) via phosphorylation of serines and threonines in
C-terminus (Dautzenberg et al., 2002, Kohout and Lefkowitz, 2003, Krasel et al., 2005,
Moore et al., 2007, Kelly et al., 2008) and the receptor signaling is then terminated. CRF 1
R

R

and CRF 2 form complexes with β-arrestins, which are bound to clathrin and β-adaptin
R

R

and form vesicles and are internalized. (Oakley et al., 2007, Markovic et al., 2008). These
desensitized receptors are then dephosphorylated, resensitized by specific phosphatases
and are recycled to the plasma membrane.
Functions of CRF and CRFRs. Hypothalamic CRF coordinates
neuroendocrine, autonomic and behavioral responses to stress (Behan et al., 1993b,
Behan et al., 1995b, Behan et al., 1996, Burrows et al., 1998a, Bale et al., 2000, Chan et
al., 2000, Bale et al., 2002, Chatzaki et al., 2002, Bale and Vale, 2004, Boorse et al.,
2006). The complexity of the stress-related mechanisms endows CRF with both positive
as well as detrimental effects. CRF promotes survival under acute or short stressful
conditions, lasting seconds to minutes, by potentiating synaptic plasticity (Behan et al.,
1995b, Cortright et al., 1995, Chen et al., 1996a, Henry et al., 2005, Florio et al., 2007b,
Holsboer and Ising, 2008), yet its excess and/ or dysregulation can contribute to a number
of detrimental effects (Linton et al., 1990, Behan et al., 1995b, Behan et al., 1996,
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Karolyi et al., 1999, Hsu and Hsueh, 2001, Lewis et al., 2001). These results are further
corroborated by overexpression of CRF in forebrain which led to learning and memory
defects (Linton et al., 1993).

Adopted from (Dautzenberg and Hauger, 2002)
Figure 7.

CRFR signaling pathways and their regulation.
CRF 1 and CRF 2 receptors signal mainly through cAMP/PKA signaling.
CRFRs also signal via the PLC/PKA pathway.
GRK3mediated CRFR desensitization, internalization and recycling
(might differ based on the specific cellular and/or neuronal background).
R

R

R

R
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Hippocampal synaptic potentiation involves CRF-CRF 1 signaling. Mice lacking CRF 1
R

R

R

R

showed attenuated synaptic plasticity (Lovejoy et al., 1998), and have memory deficits
(Contarino et al., 1999).
The extra hypothalamic effects of CRF within the CNS are predominantly
excitatory in various brain regions such as locus ceruleus (Valentino et al., 1983),
hippocampus (Siggins et al., 1985) cerebral cortex, hypothalamus and in lumbar spinal
cord motor neurons (Dunn and Berridge, 1990, Owens and Nemeroff, 1991). CRF
modifies sensory stimulus (Valentino et al., 1983), induces behavioral excitation,
stimulating activities such as rearing and grooming (Siggins et al., 1985, Britton et al.,
1986).CRF has inhibitory actions in the lateral septum, thalamus, and hypothalamic PVN
(Dunn and Berridge, 1990, Owens and Nemeroff, 1991). CRF increases GABA release
via CRF 1 in rat amygdala and hypothalamic slices (Bagosi et al., 2008, Bagosi et al.,
R

R

2012). CRF increases vigilance and decreases slow-wave sleep at doses below those
affecting locomotor activity or pituitary-adrenal function and higher doses can be
epileptogenic (Ehlers et al., 1983). CRF-mediates increase of presynaptic glutamate
release (Lovenberg et al., 1995a), as well as enhanced postsynaptic excitability which is
potentially related to CRF-induced suppression of after-hyperpolarization (Aldenhoff et
al., 1983). CRF released by IL-1 (Berkenbosch et al., 1987, Sapolsky et al., 1987,
Busbridge et al., 1989) mediates fever, thermogenesis, and ACTH release (Naitoh et al.,
1988, Busbridge et al., 1989). CRF in the leukocytes may also induce ACTH and
endorphin release (Blalock, 1989) which are responsible for natural killer activity (Irwin
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et al., 1988) and inflammatory responses. CRF family is also a novel angiogenic regulator
in endogenous and inflammatory conditions (Im et al., 2010).
To help determine the role of CRFRs mediating various biologic actions of CRF,
a number of selective peptide agonists and antagonists were discovered and developed,
based on the receptor differential ligand affinities. For example, Ucn III, has a higher
affinity to CRF 2 than CRF 1 and is commonly used as a selective CRF 2 agonist (Hsu and
R

R

R

R

R

R

Hsueh, 2001, Lewis et al., 2001). Similarly, ovine CRF is often used as a CRF 1 specific
R

R

agonist as its affinity to CRF 1 is two orders greater than CRF 2 (Ruhmann et al., 1998a).
R

R

R

R

Through mutation and artificial structural constraints, receptor-specific peptide agonists
and antagonists were developed (Ruhmann et al., 1998a, Rivier et al., 2002b, Tezval et
al., 2004, Rivier et al., 2007). For example antalarmin (ANT), and anti-sauvagine-30
specifically binds CRF 1 and CRF 2 respectively (Chen et al., 1996b, Schulz et al., 1996,
R

R

R

R

Webster et al., 1996, Holsboer and Ising, 2008).
Stress responses in general, are mediated by the activation of CRF 1 receptors
R

R

(Owens and Nemeroff, 1991, Chen et al., 1996b, Webster et al., 1996, Chen et al., 1997,
Smith et al., 1998), whereas CRF 2 receptors might be involved in the initiation of
R

R

secondary-stress responses to regain homeostasis (see review (Bale and Vale, 2004,
Gysling, 2004). These differential roles may in part be attributed to the activation of the
distinct central sources of CRF (Bagosi et al., 2008, Bagosi et al., 2012).Central
administration of CRF have anorexic effects (Vaughan et al., 1995, Spina et al., 1996,
Smagin et al., 1998) and peripheral administration has been shown to slow gastric
emptying and decrease food intake (Asakawa et al., 1999, Nozu et al., 1999).These
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effects are mediated by CRF 2 receptors. Activation of CRF 1 receptors in the brain can
R

R

R

R

suppress feeding independently of CRF 2 receptor-mediated mechanisms and independent
R

R

time-courses (Hotta et al., 1999, Reyes et al., 2001, Inoue et al., 2003). Stress stimulates
colonic motility via CRF 1 receptor activation and does not involve CRF 2 receptors
R

R

R

R

(Tache et al., 2001, Martinez et al., 2002, Tache et al., 2002). CRF 2 receptors are
R

R

predominantly involved in stress related feeding behavior (Keck et al., 2005), energy
balance (Bakshi et al., 2002), altering glucose metabolism and decreasing insulin
sensitivity in skeletal muscle, altering pancreatic β-cell (Bale et al., 2003, Chen et al.,
2006, Li et al., 2007) and cardiovascular function (Hashimoto et al., 2004, Boonprasert
et al., 2008). CRFRs play differential roles in mediating gastrointestinal regulation
following stress (Stengel and Tache, 2010). While CRF 2 inhibits gastric emptying and
R

R

small intestine motility to slow digestion, CRF 1 increases colonic motility. In some stress
R

R

related responses such as stress-induced relapse of drug seeking and stress-mediated
inhibition of reproduction, both the CRFRs may contribute to an observed response
(Sarnyai et al., 2001, Li et al., 2006, Kalantaridou et al., 2007, Wise and Morales, 2010).
The role of CRF and CRFRs is further elucidated by various genetically
engineered mouse models. a. CRF deletion mutant –CRF-knock-out (CRF KO): CRF KO
mice are phenotypically normal and display behavioral responses similar to the control
mice (Muglia et al., 1995, Dunn and Swiergiel, 1999, Weninger et al., 1999), have low
levels of basal plasma concentrations of CORT. (Muglia et al., 1995). In both the WT and
KO, stress-induced behaviors were attenuated by CRF 1 antagonists. CRF KO mice
R

R

generated from heterozygotes show adrenal insufficiency and those from the homozygous
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mating died within 24 hours due to improper lung function caused by glucocorticoid
deficiency. b. CRF overexpressing (CRF-OE) mice: Constitutive CRF-OE resulted in
elevated plasma CORT, ACTH, altered HPA axis and Cushingnoid phenotypes (StenzelPoore et al., 1992a, Dirks et al., 2002, Lu et al., 2008); reduced locomotor activity and
increased anxiety and stress (Stenzel-Poore et al., 1992a, Dedic et al., 2012), reduced
sensitivity to the anxiolytic effects of CRF 1 antagonists, GABAA and glutamate receptor
R

R

agonists in response to stress-induced hyperthermia (Vinkers et al., 2012).
To explore the functional significance of CRFR binding sites, single and double
mutant mice were generated by knocking out CRFRs (Bale et al., 2002) Koob 2001. a.
CRF 1 mutant mice: CRF 1 null mutants are normal and fertile when born from
R

R

R

R

heterozygotes. However, progeny from homozygous female died within two days after
birth due to lung dysplasia. The CRF 1 mutant mice have low plasma concentration of
R

R

CORT and showed reduced anxiogenic-like responses compared to the control littermates
(Smith et al., 1998, Contarino et al., 1999). Diminished neuronal activity and reduced
anxiety-like behaviors were also observed in conditional CRF 1 KOs, including the
R

R

neuronal circuitries of the anterior forebrain and limbic system, indicating that these
behaviors are independent of the HPA axis (Muller et al., 2003, Nguyen et al., 2006). b.
CRF 2 mutant mice: These mice exhibit normal fertility with no gross abnormality. These
R

R

mice show increased anxiety-like behavior, hypertension, increased blood vessel density
and are hypersensitive to the HPA axis mediated stress responses (Bale et al., 2000).
CRF 2 KO mice show attenuation of stress-coping behaviors and a reduced duration of
R

R

Ucn-1 induced anorexia. c. Double mutant mice: Mice with the CRF 1 and CRF 2
R
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R

R

R

receptors knocked out show decreased basal CORT and ACTH, increased PVN, CRF and
AVP. These double mutants also show an altered reactivity of the HPA axis (Preil et al.,
2001, Bale et al., 2002), as well as gender differences in exploratory emotionality and
non-genomic transmission of stress-coping traits from mothers to male offspring (Bale et
al., 2002). These results corroborate the pharmacological evidence in rats thus supporting
a role of endogenous CRF family peptides and receptors in regulation of homeostasis.
Functional roles of CRF-BP. Multiple functional roles have been suggested for
CRF-BP, which are controlled by the specific cellular or physiological context (Seasholtz
et al., 2002, Westphal and Seasholtz, 2006). CRF-BP can have an inhibitory role on the
activity of CRF or Ucn1 by sequestration from the receptors, or by mediating clearance
or degradation of the complex. This has been supported by the studies which show that
CRF-BP binds to placental CRF and prevents the inappropriate activation of CRF 1
R

R

expressing pituitary corticotropes, during pregnancy (Linton et al., 1990, Florio et al.,
2007a). Furthermore, CRF binding might trigger the clearance of CRF: CRF-BP complex
when levels of CRF increase during late pregnancy or through CRF injection and thus
decrease the plasma CRF levels (Linton et al., 1990, Woods et al., 1994). The inhibitory
role of CRF-BP is supported by in vitro cell culture assays in which pre-incubation of the
CRF with mouse or human CRF-BP showed a reduced CRF 1 -mediated ACTH release
R

R

(Potter et al., 1991, Cortright et al., 1995) and cAMP (Boorse et al., 2006). The inhibitory
role of CRF-BP is further confirmed by CRF-BP mutant mouse models (for review see
(Seasholtz et al., 2002). CRF-BP-overexpression in the anterior pituitary show unaltered
concentrations of ACTH, but increased CRF and arginine-vasopressin levels, suggesting
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a compensatory role of the hormones (Burrows et al., 1998b). When CRF-BP transgene
was overexpressed in the brain, pituitary, kidney, heart, kidney, spleen, lung, adrenals,
and liver, CRF-BP accumulated in plasma similar to that of humans (Lovejoy et al.,
1998). An increased inhibition of CRF or UCN activity was suggested in these animals
due to impaired stress response to lipopolysaccharide injection and increased weight gain
(Spina et al., 1996). In CRF-BP deficient mouse, CORT and ACTH were normal.
However, these mice showed a decreased food intake and weight gain, increased anxietylike behavior in elevated plus maze and defense withdrawal tests were exhibited by male
animals (Karolyi et al., 1999).
In contrast, studies support that CRF-BP could enhance or prolong ligand activity
by increasing its half-life and delivering it to the receptors. CRF potentiates N-methyl-Dasparate (NMDA) receptor-mediated synaptic transmission and induced cocaine-seeking
behavior in VTA, via CRF 2 , and these effects were blocked by CRF-BP-specific
R

R

antagonist, CRF6-33 (Ungless et al., 2003, Wise and Morales, 2010). While CRF-BP
exhibit an enhancing effect involving CRF 2 signaling, and all the studies demonstrating
R

R

an inhibitory role for CRF-BP involved CRF 1, these differential effects of CRF-BP on
R

R

CRF at these two receptors requires further investigation. In addition to the above roles,
CRF-BP could also mediate ligand or receptor-independent activity via interactions with
other unknown receptors or binding proteins (Chan et al., 2000).
Role and Relevance of CRF in Epilepsy
CRF is known to change the neuronal function in a rapid and reversible manner.
CRF has been implicated in a variety of neurological diseases including affective
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disorders and epilepsy (Baram and Hatalski, 1998, Hauger et al., 2006). CRF is highly
expressed in brain regions associated with developmental seizures, such as the
hippocampus and amygdala (Gray and Bingaman, 1996). For example,
intracerebroventricular injection of CRF induces seizures (Ehlers et al., 1983, Weiss et
al., 1986a, Marrosu et al., 1987, Marrosu et al., 1988) and seizures alter the expression of
CRF (Greenwood et al., 1997, Smith et al., 1997, Takahashi et al., 1997, Piekut and
Phipps, 1998, Jinde et al., 1999, Wang et al., 2001b), CRF-BP (Smith et al., 1997, Wang
et al., 2001b, Park et al., 2003) and CRF receptors (Wang et al., 2001b, An et al., 2003,
Park et al., 2003) supporting the notion that CRF is the most potent epileptogenic peptide
(Baram and Hatalski, 1998). CRF immunoreactivity has been detected in the cortex (Cha
and Foote, 1988, Arzt and Holsboer, 2006), locus coeruleus (Cha and Foote, 1988),
olfactory bulb (Bassett et al., 1992) and the limbic structures including the EC (Bassett et
al., 1992, Park et al., 2003), hippocampus (Yan et al., 1998, Park et al., 2003) and
amygdala (Bassett and Foote, 1992). CRF may also contribute to seizure-related neuronal
loss (Ribak and Baram, 1996). Additionally, picomolar amounts of CRF have been
shown to induce prolonged limbic seizures involving amygdala and the hippocampus
(Baram et al., 1992, Baram and Hatalski, 1998). The proconvulsant effects of CRF are
largely age-specific with infants being more susceptible to seizures than adults (Baram
and Schultz, 1991a).
Despite a tremendous volume of descriptive work that supports the involvement
of CRF in stress-mediated epileptogenesis; several essential issues regarding the roles of
CRF in epilepsy have not been addressed. For example, intracerebroventricular
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Table 1.

Terminology and definitions.

Terminology

Definition

Epilepsy

Brain disorder characterized by uncontrolled, excessive,
synchronous neuronal activity resulting in spontaneous,
recurrent seizures

Seizure

Clinical condition associated with a transient hyper-synchronous
neuronal discharge
Epileptogenesis Complex process, which alters a normal brain circuit into
hyperexcitable network, leading to spontaneous, recurrent
seizures. (Clark and Wilson 1999)
EpileptiformThe spike waves, sharp waves, spike and wave activity, or other
activity
rhythmic waveforms that may be associated with epilepsy
Homeostasis
The property of a system that regulates its internal environment
and tends to maintain a stable, relatively constant condition of
properties such as temperature or pH
ictogenesis
generation of epileptic seizures
SeizureAny stimuli that can precipitate a seizure in a person with or
precipitant
without epilepsy
Stress
Any disruption of homeostatic balance (Robert Sapolsky)
Stressor
A specific threat to the body
Stress response Attempt of the body to deal with the stressor
Stress
Mediators which address the specific aspects of a stressor
hormones
Inter-ictal state Interval between seizures or convulsions
Post-ictal state Altered state of consciousness after a seizure
StatusA state of continuous seizure activity
epilepticus
POU proteins
Eukaryotic transcription factors containing a bipartite DNA
binding domain referred to as the POU domain. The acronym
POU is derived from the names of three transcription factors,
the pituitary-specific Pit-1, the octamer-binding proteins Oct-1
and Oct-2, and the neural Unc-86 from Caenorhabditis elegans
(Clerc et al., 1988, Finney et al., 1988, Ingraham et al., 1988,
Sturm et al., 1988, Herr, 1998) .
U
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application of CRF can influence almost all brain regions. However, this raises several
important questions; 1) what is the action site in the brain for the effects of CRF on
epilepsy? 2) Which type of CRF receptors is involved in CRF-mediated facilitation of
epilepsy? 3) What are the signaling molecules required for CRF-mediated facilitation of
epilepsy? Further understanding of these mechanisms will advance our knowledge about
CRF-mediated integration of the synaptic signals, the firing rates of neurons, and
consequently, the input to the hippocampus via TA pathway as well as to other cortical
regions.
Ion channels modulating epileptiform activity and neuronal excitability
Neuronal hyperexcitability plays an important role in epileptogenesis. Neuronal
0T

excitability is regulated by a number of active membrane properties such as voltage-gated
or ligand-gated ion channels, passive membrane properties such as resting membrane
potential, resistance, capacitance etc. An increase in action potential (AP) frequency
enhances neuropeptide release.
Hyperpolarization Activated Cyclic Nucleotide
Channels and the Cation Current, I h
R

Changes in the expression and function of ion channels, particularly the
hyperpolarization activated cyclic nucleotide (HCN) channels (Chen et al., 2001, Wang et
al., 2001a, Bender et al., 2003, Powell et al., 2008, Marcelin et al., 2009) are known to be
mechanistically linked to epilepsy. Therefore better understanding of the mechanisms
that lead to abnormal activity is important as it provides molecular targets for
intervention in the pathological disease process.
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Figure 8.

Schematic representation of AP firing of a neuron.
1. A stimulus causes the Na+ channels to open. Once the action threshold
is reached, more Na+ channels open. Influx of Na+ causes depolarization,
as the cell membrane becomes more positive.
2. The Na+ channels close and the K+ channels open. Due to slower
kinetics of the K+ channels, the depolarization takes longer to be
completed. This results in opening of both Na+ and K+ channels at the
same time. Thus the membrane becomes neutral preventing another AP.
3. With the K+ channels open, the membrane begins to repolarize back
toward its rest potential
4. The repolarization typically overshoots the rest potential to about
-90 mV. This is called hyperpolarization which prevents the neuron from
AP firing, especially in the opposite direction. assureing the signal is
proceeding in one direction.
5. After hyperpolarization, the Na+/K+ pump brings the membrane back to
its resting state of -70 mV. (Adopted from (K. X. Charand;2002)).
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HCN channels are cation channels and contain six-transmembrane helices
(S1-S6). HCN channels generate inward cationic currents designated as I h , when the
R

R

membrane potential is hyperpolarized (Hofmann et al., 2005, Wahl-Schott and Biel,
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2009) and de-activates on depolarization (Robinson and Siegelbaum, 2003). I h produces
R

R

a depolarizing current carried by Na+ and K+ ions. Ih is critically involved in the
P

P

P

P

R

R

maintenance of the neuronal resting membrane potential, passive membrane properties,
pacemaker activity, rebound burst firing in heart and brain, reduction of dendritic
summation, as well as governing neuronal network responses (Robinson and Siegelbaum,
2003); Accilli et al. 2002; Robinson & Siegelbaum, 2003; Santoro & Baram 2003;
Poolos, 2004; Maccaferri and McBain 1996; Luthi and McCormick 1998; Magee 199;
Santoro and Baram 2003; Biel et al 2009; Hofmann et al 2005).
Its presence in stellate cells was initially established from the observation of a
sag-like response during injection of negative current steps (Alonso and Llinas, 1989,
Jones, 1994). Subsequent voltage-clamp experiments have investigated the kinetics,
voltage dependence, and pharmacology of I h in stellate cells (Richter et al., 1997,
R

R

Dickson et al., 2000, Richter et al., 2000, Nolan et al., 2007, Giocomo and Hasselmo,
2008).
HCN channels are regulated at several levels by intracellular signaling cascades
including but not limited to cAMP, PIP 2 , TRIP8b, as well as voltage-gated potassium
R

R

channels. HCN channels assemble in tetramers HCN1, HCN2, HCN3, HCN4 (Hofmann
et al. 2005) which are expressed heterologously. They are non-selective cation channels
that are distributed differentially throughout the brain (Luthi and McCormick 1998) and
exhibit developmental expression patters unique to the HCN isoforms with distinct Ih .
R

R

For example, kinetics of HCN1>HCN2 or HCN4, whereas in terms of sensitivity to
cAMP HCN1< HCN2 or HCN4. The S4 segment of the channel is positively charged and
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serves as a voltage sensor, while the C terminus contains a cyclic nucleotide binding
domain that confers regulation by the cyclic nucleotides cGMP and cAMP, which
stimulates by direct interaction with the HCN channel protein and not by protein
phosphorylation (Hofmann et al. 2005). HCN channels are blocked by ZD7288 (Richter
et al., 1997, Dickson et al., 2000, Nolan et al., 2007) and Cs+ (Alonso and Llinas, 1989,
P

P

Klink and Alonso, 1993, Dickson et al., 2000, Richter et al., 2000). I h in stellate cells, but
R

R

not mEC pyramidal cells, can be activated by the cAMP analog 8-Bromo-c-AMP
(Richter et al., 2000). Consistent with these electrophysiological data, gene expression
data from the Allen Brain Atlas indicates that mRNA levels of HCN1 and HCN2 are
particularly high in layer II of the mEC. Antibody labeling also suggests strong HCN1
expression in superficial layers of the mEC (Notomi and Shigemoto, 2004, Nolan et al.,
2007), whilst HCN2 and HCN3 show moderate expression (Notomi and Shigemoto,
2004). However, antibody labeling could reflect HCN1 channels expressed in the
dendrites of pyramidal cells with somata in layers III and V (Shah et al., 2004,
Rosenkranz and Johnston, 2006). Studies demonstrate that a reduced I h and changes in
R

R

HCN channel expression are observed in epileptic patients and animal models of
epilepsy. HCN subunits can co-associate and form heterologous systems (Much et al.,
2003). In the hippocampal tissue, heteromerization is markedly enhanced by seizures
resulting in altered properties of I h , significantly enhancing network excitability (Chen et
R

R

al 2001a; Simeone et al. 2005). I h depolarizes the resting membrane potential (Biel et al
R

R

2009; Hofmann et al 2005; Robinson & Sielgelbaum 2003) and hence a decline in I h
R

R

might be expected to reduce excitability. However, a decrease in I h was accompanied
R
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R

after enhanced neuronal excitability during kainate-induced MTLE in the EC layer III
(Shah et al. 2004) and in the hippocampus of pilocarpine-epileptic animals (Jung et al.,
2007, Marcelin et al., 2009). This inhibition of I h has been suggested to enhance
R

R

pyramidal cell dendrite excitability by increasing the availability of Ca2+ channels (Tsay
P

P

et al. 2007), as well as by amplifying the membrane resistance (Magee 1998; Stuart and
Sprutson 1998).
K+

Adopted from: Eduardo E. Benarroch, Neurology 2013;80;304-310 (Benarroch, 2013)
Figure 9.

Structure and functions of hyperpolarization-activated cyclic nucleotidegated channels.
The four subunits of HCN channels form the central pore.
Each subunit consists of a six-transmembrane core and the cytosolic
amino (N)-terminal and carboxy (C)-terminal domains.
The proximal portion of the cytosolic C-terminal domain contains the
cyclic nucleotide-binding domain (CNBD), which mediates modulation by
cyclic nucleotides, such as cAMP.
The HCN channels are permeable to Na+ and K+ and conduct a mixed
cation current,I h .
P

R

R
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P

P

P

I h blockers, such as ZD7288 and CsCl have been shown to decrease electrically induced
R

R

paroxysmal discharges in vivo, suggesting antiepileptic effects for compounds that
decrease the I h (Kitayama et al. 2003).
R

R

CRF and Ih
CRF can act on a number of ionic conductances including IK(Ca) (Aldenhoff et
al., 1983). IKir (Kuryshev et al., 1997) and I h (Qiu et al., 2005b). CRF augments I h , and
R

R

R

R

neuronal firing in the VTA dopamine neurons (Wanat et al., 2008).
Overall Hypothesis, Approach and Outcomes
Abundant evidence suggests that CRF is a potent epileptogenic neuropeptide and
has been reported to facilitate epilepsy in various other regions of the brain, such as the
hippocampus, amygdala etc. In this regard, CRF mRNA was observed in the EC
(Lovenberg et al., 1995b), but the role and relevance of CRF and its receptors in the EC is
not well established. In other brain regions CRF can increase neuronal firing rate through
activation of the cAMP-PKA pathway (Aldenhoff et al., 1983, Haug and Storm, 2000,
Jedema and Grace, 2004), and can act on a number of ionic conductances including, but
not limited to I h (Qiu et al 2005). Since the EC is an important structure involved in TLE
R

R

and mRNA of CRF receptors have been detected in the EC by in situ hybridization
(Lovenberg et al., 1995b), we hypothesized that CRF would directly interact with its
receptors and facilitates epileptiform activity via modulation of the HCN channels, and I h
R

and cAMP/PKA signaling mechanisms.
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R

Specific Aims
The work presented in this dissertation was conducted to extend the current
knowledge on the role and relevance of CRF in facilitating epilepsy. The main objective
of this project was to determine the role of CRF in facilitating epileptiform activity in the
EC using the well-established picrotoxin (PTX)-slice seizure model of epilepsy. The
specific aims were:
To investigate the role of CRF in facilitating epileptiform activity in the EC.
To determine the signaling mechanisms involved in CRF-mediated facilitation of
epileptiform activity.
To determine the role of HCN channels in CRF-mediated facilitation of
epileptiform activity.
To determine the signaling mechanisms involved in CRF-mediated modulation of
HCN channels and I h current.
R

R

To determine the role of CRF in modulating neuronal excitability.

EC

In vitro
Horizontal brain slices containing the EC

Extracellular field recordings
Whole-cell recordings

Extracellular field recordings from layer-III of the EC

aCSF: No Activity

I
II

Recording
electrode
aCSF + 100 µM PTX:
Epileptiform activity

III
IV
V/VI

200

m

aCSF : Artificial cerebro-spinal fluid
PTX : Picrotoxin

Role of CRF in PTX-induced epileptiform activity
Signaling mechanisms
Role of HCN channels

Figure 10.

Signaling mechanisms in modulation of Ih
Role of CRF in modulating neuronalexcitability

Summary of specific aims.
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To test our central hypothesis, we first examined the presence of CRF and its
receptors in the EC using immunocytochemistry and western blot techniques. We found
that the EC expresses CRF and CRF 2 receptors. However, no detectable CRF 1 was
R

R

R

R

found. Using extracellular field recordings, we examined the effects of CRF on PTXinduced epileptiform activity recorded from the entorhinal slices. The PTX-induced
seizure model resembles the simple partial and generalized forms of human epilepsy
(Fisher, 1989, Sierra-Paredes and Sierra-Marcuno, 1996, Sarkisian, 2001). PTX is a
GABA A receptor antagonist and blocks the chloride channels thus acting as a convulsant.
R

R

Apoted from : 2015 Quizlet LLC.
Figure 11.

Schematic representation of the GABAA receptor complex.
Five subunits form a transmembrane chloride-gated pore.
The receptor complex has binding sites for GABA, Benzodiapene,
Barbiturates and Picrotoxin.

Furthermore, clinical studies (Du et al., 1993) as well as experimental models of
TLE supported the preferential loss of layer III pyramidal neurons in the mEC (Schwob
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et al., 1980, Clifford et al., 1987, Du et al., 1995, Ribak et al., 1998, Jutila et al., 2001,
Bartolomei et al., 2005). Hence, we studied the role of CRF in facilitating the PTXinduced epileptiform activity in layer III of the mEC. Our results demonstrate that CRF
facilitated the induction of epileptiform activity in the presence of subthreshold
concentration of PTX which normally would not elicit epileptiform activity. Bath
application of the inhibitor for CRF-BPs, CRF6-33, also increased the frequency of PTXinduced epileptiform activity suggesting that endogenously released CRF is involved in
epileptogenesis. CRF-induced facilitation of epileptiform activity was mediated via CRF 2
R

receptors because pharmacological antagonism and knockout of CRF 2 receptors blocked
R

R

the facilitatory effects of CRF on epileptiform activity. Application of the AC inhibitors
blocked CRF-mediated facilitation of epileptiform activity and elevation of intracellular
cAMP level by application of the AC activators or phosphodiesterase inhibitor increased
the frequency of PTX-induced epileptiform activity. These data demonstrate that CRFinduced increases in epileptiform activity are mediated by an increase in intracellular
cAMP. However, application of selective PKA inhibitors reduced, but not completely
block CRF-induced enhancement of epileptiform activity suggesting that PKA is only
partially required.
Since layer II is spared and becomes hyperexcitable in various experimental
models of epilepsy and HCN channels are highly expressed in layer II stellate neurons,
we examined the role of HCN channels in CRF-mediated facilitation of epileptiform
activity. Application of ZD 7288, a blocker of the HCN channels, significantly reduced
the frequency of epileptiform activity but increased the numbers of the synchronizing
events within single epileptiform activity and the duration of individual epileptiform-

42

R

activity. In the presence of ZD 7288, CRF failed to increase the frequency of epileptiform
activity but still augmented the numbers of synchronizing events and duration in an
epileptiform activity suggesting that part of the effects of CRF on epilepsy is mediated
via HCN channels. CRF increased I h currents recorded from layer II stellate neurons via
R

R

activation of CRF 2 receptors. cAMP, not PKA was responsible for CRF-mediated
R

R

facilitation of I h . Our results provided a cellular mechanism to explain the effects of CRF
R

R

in epilepsy. Furthermore, at the cellular level, CRF depolarized the membrane potential
and increased action potential firing rate of the stellate neurons thus resulting in
facilitation of epileptiform activity in the EC.
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CHAPTER II
MATERIALS AND METHODS
Slice Preparation
Horizontal brain slices (350 µm) including the EC, subiculum and hippocampus
were cut using a vibrating blade microtome (VT1000S; Leica, Wetzlar, Germany) from
Sprague-Dawley rats (13- to 18-day-old), wild-type (WT) and CRF 2 knockout (KO) mice
R

R

(1 month) as described previously (Xiao et al., 2009b, Deng et al., 2010b, Wang et al.,
2011, Wang et al., 2012). After being deeply anesthetized with isoflurane, animals were
decapitated and their brains were dissected out in ice-cold saline solution that contained
(in mM) 130 NaCl, 24 NaHCO 3 , 3.5 KCl, 1.25 NaH 2 PO 4 , 0.5 CaCl 2 , 5.0 MgCl 2 , and 10
R

R

R

R

R

R

R

R

R

R

glucose, saturated with 95% O 2 and 5% CO 2 (pH 7.4). Slices were initially incubated in
R

R

R

R

the above solution at 35°C for 40 min for recovery and then kept at room temperature
(~24°C) until use.
Recordings of Epileptiform Activity from the Entorhinal Slices
Slices were bathed in the extracellular solution comprised (in mM) 130 NaCl, 24
NaHCO 3 , 5 KCl, 1.25 NaH 2 PO 4 , 2.5 CaCl 2 , 1.5 MgCl 2 and 10 glucose, saturated with
R

R

R

R

R

R

R

R

R

R

95% O 2 and 5% CO 2 (pH 7.4). Spontaneous epileptiform activity was induced by
R

R

R

R

including the GABA A receptor blocker PTX (100 µM) in the preceding extracellular
R

R

solution (Deng et al., 2006, Wang et al., 2013). An electrode containing the extracellular
solution was placed in layer III of the EC to record epileptiform activity. After stable
spontaneous epileptiform activity occurred, which
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usually took ~20 min, CRF was applied in the bath. The epileptiform events were initially
recorded by Clampex 9.2 and subsequently analyzed by Mini Analysis 6.0.1.
Extracellular field recordings from layer-III of the EC

aCSF: No Activity

I
II

Recording
electrode
aCSF + 100 µM PTX:
Epileptiform activity

III
IV
V/VI

200

m

aCSF : Artificial cerebro-spinal fluid
PTX : Picrotoxin

Figure 12.

Extracellular field recordings from layer III of the EC.
Recordings were made from layer III of the EC. aCSF produced no
epileptiform activity.
Whereas, addition of 100 µM PTX to the aCSF induced epileptiform
activity in the brain slices.
Whole-Cell Recordings

Whole-cell recording is a well established and most commonly used patch clamp
technique. Whole-cell configuration offers lower resistance and complete exchange
between molecules in the pipette solution and the cytoplasm, due to disruption of the
membrane patch. Whole-cell configuration has two main modes of recording: the
voltage-clamp mode, in which the voltage is held constant allowing the study of ionic
currents, and the current-clamp mode, in which the current is controlled enabling the
study of changes in membrane potential. However, the disadvantage of this technique is

45

electrode dialyzing, which is the replacement of the soluble cell contents by the contents
of the pipette solution resulting in alteration of cell properties.

Adopted from : bem.fi/book, modified from Hamill et al., 1981 (Hamill et al., 1981)
Figure 13.

Schematic representation of the whole-cell configuration.
1. The glass pipette is in contact with the cell membrane.
2. A tight gigaohm seal is formed by gentle suction; 3, more suction
causes the membrane to rupture resulting in the whole-cell configuration.
4. Exchange of pipette and cellular contents.
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In the current project, whole-cell recordings using a Multiclamp 700B amplifier
(Molecular Devices, Sunnyvale, CA) in current- or voltage-clamp mode were made from
the stellate neurons in layer II of the medial EC, visually identified with infrared video
microscopy (Olympus BX51WI) and differential interference contrast optics. The
recording electrodes were filled with (in mM) 100 potassium (K+)-gluconate, 0.6 EGTA,
P

P

2 MgCl 2 , 8 NaCl, 2 ATP 2 Na, 0.4 GTPNa, 40 HEPES, and 7 di-tris-phosphocreatine (pH
R

R

R

R

7.4, 290–300 mOsm/L). The extracellular solution comprised (in mM) 130 NaCl, 24
NaHCO 3 , 3.5 KCl, 1.25 NaH 2 PO 4 , 2.5 CaCl 2 , 1.5 MgCl 2 , and 10 glucose, saturated with
R

R

R

R

R

R

R

R

R

R

95% O 2 and 5% CO 2 (pH 7.4).
R

R

R

R

Action potentials (APs) were recorded in the preceding extracellular solution
supplemented with bicuculline (10 μM) and CGP55845 (1 μM) to block GABA A and
R

R

GABA B responses, respectively, and 6,7-dinitroquinoxaline-2,3-dione (DNQX, 10 μM)
R

R

and DL-2-amino-5-phosphonopentanoic acid (DL-APV, 50 μM) to block glutamatergic
transmission. For most of the cells, a positive current injection was required to bring the
resting membrane potential (RMP) to ∼−50 mV to induce AP firing. CRF was applied
after the AP firing had been stable for 5∼10 min. To avoid potential desensitization
induced by repeated applications of CRF, only one cell was recorded from each slice.
Data were filtered at 2 kHz, digitized at 10 kHz, acquired online, and analyzed after line
using pCLAMP 9 software (Molecular Devices). Frequency of APs was calculated by
Mini Analysis 6.0.1 (Synaptosoft, Decatur, GA).
Holding currents (HCs) at −60 mV were recorded from layer II stellate neurons.
The preceding extracellular solution was supplemented with TTX (0.5 μM) to block AP
firing. HCs at −60 mV were recorded every 3 s and then averaged per minute. We
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subtracted the average of the HCs recorded for the last minute prior to the application of
CRF from those recorded at different time-points to zero, the basal level of HCs, for
better comparison.
Perforated Patch Clamp Recordings
Perforated patch clamp method is very similar to the whole-cell configuration. In
this method the patched membrane is not ruptured by suction after the formation of the
gigaohm seal. The electrode solution contains small amounts of an antifungal or
antibiotic agent, such as amphotericin-B, nystatin, or gramicidin, which diffuses into the
10T
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Amphotericin B
Solution

Amphotericin B - Pore

Adopted from: the National Institute for Physiological Sciences, 2009
Figure 14.

Illustration of perforated patch clamp recording.
The electrode solution contains small amounts of antibiotic agent, such as
amphotericin-B, which diffuses into the membrane patch and forms small
pores in the membrane.
Only monovalent ions can pass through the pore and divalent and second
messenger components are retained within the cell interior.
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membrane patch and forms small pores in the membrane thus providing electrical access
to the cell interior (Linley, 2013).
The advantage of the perforated patch clamp technique is that it allows
equilibration of only small monovalent ions between the patch pipette and the cytosol.
However, larger divalent ions such as Ca2+ and signaling molecules such as cAMP,
P

P

cannot permeate through the pores. This helps in the maintenance of endogenous levels
of most intracellular signaling molecules, and reduced current rundown as in cellattached recordings (Linley, 2013). On the other hand, the disadvantages of using the
perforated patch are: it can take a significant amount of time for the antibiotic to perforate
the membrane; due to the perforation process the patch may rupture resulting in wholecell mode and thus the antibiotic contaminates the entire cell contents; perforated patch
offers a higher access resistance compared to that of the whole-cell recordings as the
pipette tips are occupied by the cell membrane which may decrease current resolution
and increase recording noise.
In our current experiments, we used perforated-patch recordings to record HCNchannel currents (I h ) from layer II stellate neurons in horizontal slices as described
R

R

previously (Deng and Lei, 2007, Deng et al., 2010a). The extracellular solution
comprised (in mM) 130 NaCl, 24 NaHCO 3 , 3.5 KCl, 1.25 NaH 2 PO 4 , 2.5 CaCl 2 , 1.5
R

R

R

R

R

R

R

R

MgCl 2 and 10 glucose, saturated with 95% O 2 and 5% CO 2 (pH 7.4). Tetrodotoxin (0.5
R

R

R

R

R

R

µM) was included in the extracellular solution to block action potentials. Recording
pipettes were tip-filled with the intracellular solution comprising 100 K+-gluconate, 0.6
P

P

EGTA, 5 MgCl 2 , 8 NaCl, 2 ATP 2 Na, 0.3 GTPNa and 40 HEPES (pH 7.3) and then backR

R

R

R

filled with freshly prepared K+-gluconate intracellular solution containing amphotericin B
P

P
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(200 µg/ml, Calbiochem, San Diego, CA). Patch pipettes had resistance of 6-8 MΩ when
filled with the preceding solution. A 5-mV hyperpolarizing test pulse was applied every 5
s to monitor the changes of the series resistance and the process of perforation. Stable
series resistances (50-70 MΩ) were usually obtained ~30 min after the formation of
gigaohm seals. For those cells showing abrupt reduction in series resistance during
membrane perforation suggesting the simultaneous formation of whole-cell
configuration, experiments were terminated. Perforated-patch configurations were
verified by examining the series resistance again at the end of the experiments. Data were
included for analysis only from those cells showing <15% alteration of series resistance.
Western Blot
Brain tissues for western blot experiments were taken from 10 rats (18-day-old).
For each rat, horizontal brain slices were cut initially and the medial EC region was
punched out from the slices under a microscope. The isolated brain region was lysed in
tissue protein extraction buffer containing protease inhibitors (Pierce, Rockford, IL). The
lysates were centrifuged at 10,000×g for 10 min to remove the insoluble materials and
protein concentrations in the supernatant were determined (Bradford, 1976). An
equivalent of 40 µg total protein was loaded to each lane. Proteins were separated by
12% SDS–PAGE and transferred to the polyvinylidene difluoride (PVDF, Immobilon-P,
Millipore, Billerica, MA) membranes using an electrophoretic transfer system (BioRad,
Hercules, CA). Blots were blocked with 5% powdered milk, and then incubated with
individual primary antibodies (anti-CRF, anti-CRF 1 or anti-CRF 2 , 1:500) overnight at
R

R

R

R

4°C followed by incubation with the secondary antibody (donkey anti-goat IgG-HRP,
1:2000) for 1 h at room temperature. Tris-buffered saline with 1% Tween-20 was used to
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wash the blots 3 times (10 min each) after incubation with both primary and secondary
antibodies. β-actin was used as a gel loading control for the tissue homogenates. The
blots were developed with enhanced SuperSignal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL). Immunoreactive bands were visualized and detected on
polyvinylidene difluoride membrane and analyzed by LabWorks 4.5 software on a UVP
Biospectrum Imagining System (UVP, Upland, CA).
Table 2. Antibodies used for western blot.
Antibody

Source

Dilution

anti-CRF

Goat

1 500

anti-CRF 1

Goat

1 500

anti-CRF 2

Goat

1 500

donkey anti-goat IgG-HRP

Donkey

1 2000

R

R

Immunocytochemistry
The detailed procedures for immunocytochemistry were described previously (Lei
et al., 2007, Deng and Lei, 2008, Deng et al., 2009, Xiao et al., 2009a, Deng et al.,
2010a). Briefly, rats (18-day-old) were anaesthetized with pentobarbital sodium (50
mg/kg) and then perfused transcardially with 0.9% NaCl followed by 4%
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). Brains were rapidly
removed and postfixed in the same fixative for an additional 2 h. After postfixation,
brains were cryoprotected with 30% sucrose in PBS for 12 h and then cut into 20 µm
slices in thickness horizontally in a Leica cryostat (CM 3050 S) at −21°C. Slices were
washed in 0.1 M PBS and then treated with 0.3% hydrogen peroxide (H 2 O 2 ) for 30
R
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R

R

R

minutes to quench endogenous peroxidase activity. After being rinsed in 0.1 M PBS
containing 1% Triton X-100 and 1.5% normal donkey serum for 30 min, slices were
incubated with the primary antibodies (goat anti-CRF antibody, sc-1761; anti-CRF 1
R

R

antibody, sc-12381; anti-CRF 2 antibody, sc-20550; Santa Cruz Biotechnology Inc.) at a
R

R

dilution of 1:100 at 4°C for 12 h. Slices were incubated at room temperature with
biotinylated donkey anti-goat IgG (ABC Staining System, Santa Cruz Biotechnology
Inc.) for 1 h and then with avidin-biotin complex (ABC Staining System) for 30 min.
After each incubation, slices were then washed three times for a total of 30 min.
Diaminobenzidine (ABC Staining System) was used for a color reaction to detect the
positive signals. Finally, slices were mounted on slides, dehydrated through an alcohol
range, cleared in xylene and covered with cover-slips. Slides were visualized and
photographed with a Leica microscope (DM 4000B). We stained 5–6 nonadjacent
sections and each staining was repeated by using 3 rats.
Table 3.

Antibodies used for immunocytochemistry.
Antibody

Source

Dilution

anti-CRF

Goat

1 100

anti-CRF 1

Goat

1 100

anti-CRF 2

Goat

1 100

biotinylated donkey anti-goat IgG

Donkey 1:100

R

R

Statistical Analysis
All data were presented as the means ± S.E.M. For statistical analysis of the
effects of CRF on epileptiform activity, the averages of 3-5 min of the frequency of
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epileptiform activity before and after the application of CRF were compared. CRF
concentration-response curves were fitted by the Hill equation: I = I max ×
P

P

R

R

{1/[1 + (EC 50 /[ligand])n]}, where I max is the maximum response, EC 50 is the
R

R

P

P

R

R

R

R

concentration of ligand producing a half-maximal response, and n is the Hill coefficient.
P

P

P

P

I h were determined by subtracting the instantaneous currents (I Ins ) from the steady-state
R

R

R

R

currents (I ss ). Student's paired or unpaired t test or analysis of variance (ANOVA) was
R

R

used for statistical analysis as appropriate; P values were reported throughout the text and
significance was set as P<0.05. N number in the text represents the slices or cells
examined.
Chemicals
CRF was purchased from American Peptide Company (Sunnyvale, CA). The
following reagents were products of TOCRIS (Ellisville, MO): K41498, astressin 2B,
NBI 27914, CP 154526, MDL 12330A, SQ 22536, forskolin, 3,7-dihydro-1-methyl-3-(2methylpropyl)-1H-purine-2,6-dione(IBMX), KT 5720, Rp-cAMPS, CGP55845,
bicuculline, 6,7-dinitroquinoxaline-2,3-dione (DNQX) and dl-2-amino-56T

6T

phosphonopentanic acid (dl-APV). The other chemicals were purchased from Sigma6T

6T

Aldrich (St. Louis, MO).
Antibodies
Goat anti-CRF antibody, sc-1761; anti-CRF 1 antibody, sc-12381; antiR

R

CRF 2 antibody, sc-20550; Santa Cruz Biotechnology Inc., biotinylated donkey anti-goat
R

R

IgG (ABC Staining System, Santa Cruz Biotechnology Inc.), avidin-biotin complex and
Diaminobenzidine (ABC Staining System).
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Table 4.

Signal transduction and ion channel activators and inhibitors.
Compound

Concentration Used

Target

K41498

0.1 µM

CRF 2 antagonist

astressin 2B

0.1 µM

CRF 2 antagonist

NBI 27914

1 µM

CRF 1 antagonist

CP 154526

1 µM

CRF 1 antagonist

CRF6-33

1 µM

CRF-BP inhibitor

MDL 12330A

50 µM

AC inhibitor

SQ 22536

400 µM

AC inhibitor

Forskolin

20 µM

AC activator

IBMX

500 µM

PDE inhibitor

KT 5720

1 µM

PKA inhibitor

Rp-cAMPS

100 µM

PKA inhibitor

ZD7288

100 µM

HCN- channel blocker

R

R

R

R

R0T

R0T

0T

R0T

0T

R0T

0T

0T

Animals
Sprague-Dawley rats were purchased from Harlan Laboratories. CRF 2
R

R

homozygous KO mice (Stock number: 010842; Strain name: B6; 129-crhr2tm1jsp/J) and
P

P

WT mice (from the same colony) were bought from Jackson Laboratories. This study was
carried out in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiments of the University of
North Dakota (0702-2). All efforts were made to minimize suffering.
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CHAPTER III
RESULTS
Expression of CRF and CRF2 in the EC
Since mRNA of CRF receptors has been detected in the EC by in situ
hybridization (Lovenberg et al., 1995b) we first examined the expression of CRF and
CRF receptors in the EC of rats using immunocytochemistry and western blot analysis.
The anatomical location of the EC and the divisions of individual layers in slice of rats
were described previously (Deng et al., 2007, Xiao et al., 2009a). Strong
immunoreactivity for CRF (Figure 15 A, upper panel) and CRF 2 (Figure 15C, upper
R

R

panel) were detected in the EC whereas there was no detectable immunoreactivity for
CRF 1 in the EC (Figure 15B, upper panel). Western blot demonstrates that a band of ~20
R

R

kDa (Figure 15A, lower panel) close to the reported molecular mass of CRF (Lauber et
al., 1984, Watabe et al., 1991, Saoud and Wood, 1996) and a band of ~63 kDa (Figure
15C, lower panel) close to the reported molecular mass of CRF 2 (Miyata et al., 1999)
R

R

were detected in the lysate of the EC. The specificities of the antibodies were confirmed
by preabsorption of the antibodies with their corresponding blocking peptides blocked the
detection of the bands (Figure 15, lower panel right). Whereas the molecular mass of rat
brain CRF 1 was found to be 76–80 kDa (Radulovic et al., 1998, Spiess et al., 1998) there
R

R

was no conspicuous band within this range (Figure 15B, lower panel) demonstrating that
there is no expression of CRF 1 in the EC. Together, these data demonstrate that the EC
R

R
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expresses CRF and CRF 2 with no detectable expression of CRF 1 (Kurada et al., 2014),
R

R

R

R

consistent with previous results obtained by in situ hybridization (Lovenberg et al.,
1995b).

Figure 15.

The entorhinal neurons express CRF and CRF 2 receptors but not CRF 1
receptors.
A: Immunoreactivity for CRF (upper) and detection of CRF by western
blot (lower). Upper right: high magnification of the region marked in the
left.
B: Lack of immunoreactivity (upper) and protein band (lower) for CRF 1
receptors.
C: The entorhinal neurons showed immunoreactivity (upper) for CRF 2
receptors and western blot detected a band close to the molecular mass of
CRF 2 receptors in the lysates of the EC (lower).
7T

7T

R

R

R

R

R

R

R

R
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R

R

CRF Facilitates Epileptiform Activity Recorded from the EC
in Horizontal Slices
We studied the roles of CRF in epilepsy by recording PTX-induced epileptiform
activity from layer III of the EC in horizontal slices (Figure 16) as described previously
by Wang et al., stable epileptiform events occurred in ~20 min after bath perfusion of
PTX (Wang et al., 2013). We therefore began to record basal epileptiform activity after
perfusion of PTX for ~20 min. In this in vitro slice seizure model, application of CRF
(0.1 µM) in the perfusion solution significantly increased the frequency of the
epileptiform activity (n = 7 slices, P<0.001, Figure 16).

Figure 16.

CRF increases the frequency of epileptiform activity induced by PTX.
A 1 : Bath application of CRF increased the frequency of epileptiform
activity recorded from layer III of the EC in horizontal slices.
A 2 : Normalized events showing an increase in epileptiform events after
the application of CRF
Control : 100 µM PTX in aCSF, CRF : Control + 0.1 µM CRF,
Wash : 100 µM PTX in aCSF.
R

R

R

R
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CRF facilitates epileptiform activity recorded from the EC
in mini-slices

The above experiments were performed in the horizontal slices containing the EC,
hippocampus and other cortices. Whereas the connections among the EC and other brain
regions such as the hippocampus are unlikely to be complete after cutting of the slices,
we still tested whether the effects of CRF on epileptiform activity were due to the action
of CRF on structures other than the EC. We therefore cut the medial EC out under a
microscope and recorded PTX-induced epileptiform activity from layer III of the EC in
this “mini slice” (Figure 17).

Figure 17.

Micrograph of the mini-slice.

As shown in Figure 18 A 1 -A 2 , bath application of CRF (0.1 µM) still
R

R

R

R

significantly increased the frequency of the epileptiform activity in the mini slices (n = 8,
P = 0.001, Figure. 18 A 1 -A 2 ) excluding the possibility that the action site of CRF is
R

R

R

R

outside of the EC. Because CRF-induced increase in epileptiform activity recorded from
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the horizontal slices was statistically indistinguishable from that recorded from the mini
slices, (P = 0.98, two-way ANOVA), we used the horizontal slices for the rest of the

Figure 18.

CRF increases the frequency of epileptiform activity induced by PTX in
mini-slices.
A 1 : Bath application of CRF increased the frequency of epileptiform
activity recorded from layer III of the EC in “mini slices” for which the
hippocampus and other cortices were cut away.
A 2 Normalized events showing an increase in epileptiform events after the
application of CRF.in “mini slices”
B: Concentration-response curve of CRF-induced facilitation of
epileptiform activity. Numbers in the parentheses were numbers of slices
recorded.
R

R

R

R
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experiments simply for the convenience of experiments. The EC 50 for CRF was measured
R

R

to be 19.6 nM Figure. 18B. Because the maximal effect of CRF could be observed at 0.1
µM, we used this concentration of CRF for the rest of experiments.

CRF Facilitates the Susceptibility of Epilepsy in the EC
We then tested whether CRF facilitates the susceptibility of epilepsy. Bath
application of the subthreshold concentration of PTX (10 µM), instead of 100 µM PTX,
used in previous experiments, for 30 min did not induce epileptiform activity (Figure 19.
A 1 -A 2 ), but subsequent co-application of CRF (0.1 µM) induced robust epileptiform
R

R

R

R

activity (Figure 19. A 1 -A 2 ), suggesting that CRF increases the susceptibility of epilepsy.
R

Figure 19.

R

R

R

CRF facilitates the susceptibility of epilepsy.
A 1 : Bath application of subthreshold concentration of PTX (10 µM) for
30 min failed to induce epileptiform activity whereas co-application of
CRF induced robust epileptiform activity.
A 2 : Normalized events showing CRF induced epileptiform activity in the
presence of subthreshold PTX.
R

R

R

R
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Endogenously Released CRF Facilitates Epileptiform Activity
The above results suggest that endogenously released CRF may play a role in
epileptogenesis. As shown in Figure 15A, high density of CRF immunoreactivity was
detected in the EC. Since there is evidence that the neuronal release of neuropeptides
requires higher stimulation frequencies than that required by monoamine
neurotransmitters colocalized in the same neuron (Lundberg and Hokfelt, 1983, Consolo
et al., 1994) we hypothesized that PTX (100 µM)- induced epileptiform activity that may
have increased CRF release, which further facilitates the epileptiform activity. We
therefore tested this hypothesis by probing the roles of endogenously released CRF in
PTX-induced epileptiform activity. Because CRF binds to the CRF-BP which buffers the
amount of free CRF in the extracellular compartment (Jahn et al., 2005), we superfused
slices with CRF6-33 (1 µM), a comparative inhibitor of the CRF-BP This peptide was
used successfully to test the endogenous role of CRF in facilitating intracellular Ca2+
P

P

release in midbrain dopamine neurons (Riegel and Williams, 2008). Bath application of
CRF6-33 significantly increased the frequency of epileptiform activity induced by PTX
(236±39% of control, n = 4, P = 0.04, Figure 20 A 1 -A 2 ). As will be shown below, CRFR

R

R

R

mediated increases in epileptiform activity were mediated by activation of CRF 2
R

R

receptors. Pre-incubation of slices with and continuous bath application of the selective
CRF 2 antagonist, K41498 (0.1 µM) blocked CRF6-33-induced augmentation of
R

R

epileptiform activity (98±9% of control, n = 5, P = 0.82, Figure 20 B). These data
together demonstrate that endogenously released CRF facilitates epileptiform activity.
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CRF Increases Epileptiform Activity via Activation of CRF2 Receptors
We next probed the roles of the receptors and the signaling mechanisms
involved in the CRF-mediated facilitation of epileptiform activity, using various
pharmacological challenges (Figure 21, Table 5). In order to overcome the problem of
non-specificities of the inhibitors used in the blockade of the signaling cascade, we took
care of the following parameters: i). Used more than one type of the inhibitor ii).
Carefully chose the effective concentrations and IC 50 values of the inhibitors given in the
R

R

literature. iii).To ensure pharmacological effectiveness, we pre-treated the slices with the
inhibitors as described in the literature prior to the application of CRF. Pretreatment of
slices with and continuous bath application of K41498 (0.1 µM), a CRF 2 antagonist,
R

R

significantly reduced CRF-induced increases in epileptiform activity (122±10% of
control, n = 11 slices, P<0.001 vs. CRF alone, Figure 22 A). Application of astressin 2B
(0.1 µM), another CRF 2 antagonist, in the same fashion blocked CRF-induced increases
R

R

in epileptiform activity (113±9% of control, n = 7, P = 0.22 vs. baseline, Figure 22 B).
We further confirmed the role of CRF 2 receptors by using CRF 2 receptor KO mice.
R

R

R

R

Application of CRF (0.1 µM) increased the epileptiform activity in WT mice (n = 14
slices from 4 mice, P<0.001, Figure 22 C) but did not facilitate the epileptiform activity
in CRF 2 receptor KO mice (n = 12 slices from 3 mice, P = 0.59, Figure 22 D) further
R

R

confirming the requirement of CRF 2 receptors.
R

R
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Figure 20.

Endogenously Released CRF Facilitates Epileptiform Activity..
A 1 -A 2 : Bath application of CRF6-33, a comparative inhibitor of the CRFbinding protein, significantly increased the frequency of epileptiform
activity via activation of CRF 2 receptor s.
B: Pre-application of K41498, a selective CRF 2 antagonist, blocked
CRF6-33-induced increases in the frequency of epileptiform activity.
R

R

R

R

R

R

R
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R

CRF
CRF Receptors
A. MDL 12330A
B. SQ 22536
(AC Inhibitors)
Forskolin
(AC Activator)

Adopted from : Holmes, A. et al., Trends Pharmacol Sci 24 (11), 580 (2003)
Figure 21.

Elucidation of signaling mechanisms using various inhibitors (in red) and
activators (green).
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Table 5.

Peptide and small-molecule CRFR antagonistsa (Zorrilla et al., 2003).

Common
name

CRF receptor
binding affinity

CP154526

CRF 1 CRF 2
(nm) (nm)
2.7
>10 000

NBI27914

2c

R

R

Chemical structure

References

N-Butyl-N-[2<comma>5dimethyl-7(2<comma>4<comma>6trimethylphenyl)-7Hpyrrolo[2<comma>3d]pyrimidin-4-yl]-N ethylamine

(Seymour et al.,
2003)

R

R

P

(McCarthy et al.,
>10 000c 5-Chloro-N(cyclopropylmethyl)-21999)
methyl-N-propyl-N′(2<comma>4<comma>6trichlorophenyl)-4<comma>6pyrimidinediamine
P

Astressin2- >50
B
0

1.3

Cyclo(31–34)[dPhe11<comma>His12<comm
a>CαMeLeu13<comma>39<c
omma>Nle17<comma>Glu31
<comma>Lys34]acetylsauvagine8–40

(Rivier et al., 2002a)

K41498

0.7

[dPhe11<comma>His12<comm
a>Nle17]-sauvagine11–40

(Ruhmann et al.,
1998b, Lawrence et
al., 2002)

425

a. Binding data represent Ki values (inhibition constants) at rat or human CRF
receptors as reported in the associated table reference, unless otherwise indicated.
b.50% inhibitory binding concentrations (IC 50 ) from (Rivier et al., 2002a) using
cloned human CRF 1 and murine CRF 2(b) receptors with 125I-[Tyr0,Glu1,Nle17]sauvagine as the competitive radio ligand.
c. K i value for rat CRF receptors as reviewed in (Gilligan et al., 2000).
R

R

R

R0T

0T

R

R0T

0T

R
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R

0T

0T

0T

0TP

P

P

P

P

P

P

P

Table 6:

Signaling cascade inhibitors and activators used.

Common
name
MDL
12,330A
SQ 22536

Forskolin

IBMX
KT 5720

Rp-cAMPs

ZD 7288

Chemical structure

Target

References

(±)-N-[(1R*,2R*)-2Phenylcyclopentyl]-azacyclotridec1-en-2-amine hydrochloride
9-(Tetrahydro-2-furanyl)-9H-purin6-amine

AC Inhibitor

(Guellaen et al., 1977,
Hunt and Evans, 1980,
van Rossum et al., 2000)
(Harris et al., 1979,
Fabbri et al., 1991,
Hourani et al., 2001)

[3R(3α,4aβ,5β,6β,6aα,10α,10aβ,10bα)]5-(Acetyloxy)-3ethenyldodecahydro-6,10,10btrihydroxy-3,4a,7,7,10apentamethyl-1H-naphtho[2,1b]pyran-1-one
3,7-Dihydro-1-methyl-3-(2methylpropyl)-1H-purine-2,6-dione
(9R,10S,12S)-2,3,9,10,11,12Hexahydro-10-hydroxy-9-methyl1-oxo-9,12-epoxy-1Hdiindolo[1,2,3-fg:3',2',1'kl]pyrrolo[3,4i][1,6]benzodiazocine-10carboxylic acid, hexyl ester
(R)-Adenosine, cyclic 3',5'(hydrogenphosphorothioate)
triethylammonium

AC Activator

(Awad et al., 1983,
Seamon et al., 1983,
Laurenza et al., 1989,
Kim et al., 2005)

PDE Inhibitor

(Freitag et al., 1998,
Lepski et al., 2013)
(Kase et al., 1987,
Gadbois et al., 1992,
Cabell and Audesirk,
1993)

[4-(N-Ethyl-N-phenylamino)-1,2
dimethyl-6-(methylamino)
pyrimidinium chloride ICI-D7288
N-Ethyl-1,6-dihydro-1,2-dimethyl6-(methylimino)-N-phenyl-4pyrimidinamine hydrochloride]

HCN channel
Inhibitor
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AC Inhibitor

PKA Inhibitor

PKA Inhibitor

(Van Haastert et al.,
1984, Rothermel and
Parker Botelho, 1988,
Dostmann et al., 1990,
Fu et al., 2008)
(BoSmith et al., 1993,
Harris and Constanti,
1995, Green et al., 1996,
Klar et al., 2003)

Figure 22.

CRF facilitates epileptiform activity via activation of CRF 2 receptors.
A: Pretreatment of slices with and continuous bath application of K41498,
a selective CRF 2 antagonist, blocked CRF-mediated increases in
epileptiform activity.
B: Pretreatment of slices with and continuous bath application of
astressin 2B, another selective CRF 2 antagonist, blocked CRF-mediated
increases in epileptiform activity.
C: Application of CRF increased epileptiform activity in WT mice.
D: Application of CRF did not induce an increase in epileptiform activity
in CRF 2 KO mice.
R

R

R

R

R

R

R

R

Whereas these data demonstrate the requirement of CRF 2 receptors, we also
R

R

examined the roles of CRF 1 receptors. CRF-induced increases in epileptiform activity
67
R

R

were not altered significantly (vs. CRF alone) in slices treated with NBI 27914 (1 µM, n
= 8,P= 0.78, Figure 23 A) or CP 154526 (1 µM, n = 12,P= 0.87, Figure 23 B), two
6T

6T

0T

0T

6T

6T

selective CRF 1 antagonists.
R

Figure 23.

R

CRF-mediated facilitation of epileptiform activity does not involve CRF 1
receptors.
A: Pretreatment of slices with and continuous bath application of
NBI 27914, a selective CRF 1 antagonist, failed to alter significantly CRFmediated increases in epileptiform activity.
B: Pretreatment of slices with and continuous bath application of
CP 154526, another selective CRF 1 antagonist, did not change the
facilitatory effect of CRF on epileptiform activity.
R

R

R

R

R

Roles of the AC/cAMP/PKA Pathway in CRF-Induced
Increases in Epileptiform- Activity
Because CRF 2 receptors are coupled to AC/cAMP/PKA pathway and there is
R

R

strong evidence demonstrating that cAMP and PKA signals exert a tonic control of
epilepsy (Boulton et al., 1993, Yechikhov et al., 2001, Higashima et al., 2002, VazquezLopez et al., 2005, Ure and Altrup, 2006, Ristori et al., 2008), we tested the roles of this
pathway in CRF-mediated facilitation of epileptiform activity (Figure 24). Slices were
pretreated with the selective AC inhibitor MDL 12330A (50 µM) for ~20 min and the
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R

same concentration of MDL 12330A was included in the PTX-containing extracellular
solution and applied in the bath before and during the application of CRF. In this
condition, bath application of CRF (0.1 µM) did not significantly increase the frequency
of the epileptiform activity (n = 11, P = 0.14, Figure 24 A). Similarly, application of
SQ 22536 (400 µM), another AC inhibitor, in the same fashion also blocked CRFmediated facilitation of the frequency of epileptiform activity (n = 7, P = 0.2, Figure 24
B). These data together indicate that CRF increases epileptiform activity via activation of
AC. Activation of AC increases the generation of cAMP. We next tested whether
elevation of cAMP level mimics the effect of CRF. Bath application of forskolin
(20 µM), an AC activator, significantly increased the frequency of epileptiform activity
(170±12% of control, n = 13, P<0.001, Figure 24 C). Moreover, application of IBMX
(500 µM), a phosphodiesterase (PDE) inhibitor to inhibit the degradation of cAMP, also
significantly increased the frequency of epileptiform activity (253±23% of control, n =
15, P<0.001, Figure 24 D). These data together demonstrate that CRF-induced increases
in the frequency of epileptiform activity are related to an increase in intracellular cAMP
level.
We next tested the roles of PKA in CRF-induced facilitation of epileptiform
activity. Slices were pretreated with the selective PKA inhibitor KT 5720 (1 µM) for ~20
min and the same concentration of KT 5720 was included in the PTX-containing
extracellular solution and applied in the bath before and during the application of CRF. In
this condition, bath application of CRF (0.1 µM) induced a statistically smaller increase
in the frequency of epileptiform activity (130±8% of control, n = 10, P = 0.005 vs. CRF
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alone, Figure 25 A). Application of Rp-cAMPS (100 µM), another specific PKA
inhibitor, in the same fashion also significantly diminished CRF-mediated facilitation of

Figure 24.

CRF facilitates epileptiform activity via activation of AC/cAMP pathway.
A: Pretreatment of slices with MDL-12330A, a selective AC inhibitor,
blocked CRF-mediated increases in epileptiform activity.
B: Pre-application of SQ-22536, another AC inhibitor, blocked CRFmediated facilitation of epileptiform activity.
C: Bath application of forskolin, an AC activator, increased the frequency
of epileptiform activity.
D: Bath application of IBMX, a PDE inhibitor, enhanced the frequency of
epileptiform activity.
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the frequency of epileptiform activity (133±4% of control, n = 9, P = 0.004 vs. CRF
alone, Figure 25 B). These data together demonstrate that PKA also plays a role in CRFmediated increase in epileptiform activity.

Figure 25.

CRF facilitates epileptiform activity via partial involvement of PKA
pathway.
A: Pretreatment of slices with KT 5720, a selective PKA inhibitor,
partially blocked CRF-mediated enhancement of the frequency of
epileptiform activity.
B: Pretreatment of slices with Rp-cAMPS, another specific PKA inhibitor
partially blocked the facilitatory effect of CRF on epileptiform activity.

Roles of HCN-Channels in CRF-Mediated Facilitation of Epileptiform Activity
We tested whether HCN channels, in general, are involved in CRF-induced
facilitation of epileptiform activity for the following reasons. First, CRF has been shown
to facilitate HCN-channels (Qiu et al., 2005a, Wanat et al., 2008, Giesbrecht et al., 2010).
Second, entorhinal neurons express robust HCN-channels (van der Linden and Lopes da
Silva, 1998, Dickson et al., 2000). Third, HCN-channels are involved in epilepsy in other
regions of the brain (Huang et al., 2009, Noam et al., 2011). Bath application of the
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selective HCN-channel blocker, ZD 7288 (100 µM) significantly reduced the frequency
of epileptiform activity to 54±7% of control (n=9, P<0.001, Figure 26 A, B) and bath
application of CRF in the presence of ZD 7288 did not further elevate the frequency of
epileptiform activity (53±12% of the base line before the application of ZD 7288, n=9,
P=0.94 vs. ZD 7288 alone, Figure 26 A, B). These data suggest a role for HCN-channels
in CRF-induced facilitation of epileptiform activity.
However, further analysis by measuring the numbers of synchronizing events,
reminiscent of the interictal activity (between-seizures), in single ictal (seizure)-like
epileptiform discharges and the duration of individual epileptiform activity demonstrated
that ZD 7288 significantly increased the numbers of synchronizing events in single
epileptiform activity (322±59% of control, n=9, P=0.009, Figure 26 A) and the duration
of individual epileptiform activity (230±34% of control, n=9, P=0.002, Figure 26 A)
suggesting that HCN-channels alter the patterns of epileptiform activity. In the presence
of ZD 7288, bath application of CRF further increased the number of synchronizing
events in single epileptiform activity (568±92% of control, n=9, P<0.001 vs. ZD 7288
alone, Figure 26 C) and the duration of individual epileptiform activity (366±62% of
control, n=9, P=0.008 vs. ZD 7288 alone, Figure 26 C). These data suggest that CRF
facilitates epileptiform activity via multiple mechanisms and HCN-channels contribute to
but are not the sole performer in CRF-mediated facilitation of epilepsy.
If HCN-channels are involved in CRF-mediated facilitation of epileptiform
activity, CRF should modulate HCN-channel activity.
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Figure 26.

HCN channels are involved in CRF-mediated facilitation of epileptiformactivity.
A: Epileptiform activity recorded from a slice in response to sequential
applications of ZD 7288 and CRF. Arrows indicate the expansion of a
single epileptiform activity. Note the difference of the time in the scale
bar.
B: Summarized time course of the frequency of the epileptiform activity in
response to the sequential applications of ZD 7288 and CRF. Note that
application of ZD 7288 significantly reduced the frequency of
epileptiform activity and application of CRF in the presence of ZD 7288
failed to further increase the frequency of epileptiform activity.
C: Summarized data for the number of synchronizing events in individual
epileptiform activity and the duration of single epileptiform activity in
response to ZD 7288 and CRF. Data were normalized to the control level
before application of ZD 7288. Note that CRF still increased the number
of synchronizing events in single epileptiform activity and the duration of
epileptiform activity in the presence of ZD 7288.
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We next tested whether CRF modulates HCN-channel function by recording I h
R

R

from the stellate neurons in layer II of.the EC, because these neurons express robust
HCN-channels (van der Linden and Lopes da Silva, 1998, Dickson et al., 2000)
Stellate Neuron Identification:

Figure 27.

Stellate neuron identification.
A: Schematic illustration of the recording location in the EC. DG, dentate
gyrus; Sub, subiculum; PER, perirhinal; R, recording electrode.
B: a stellate neuron identified under an infrared video microscopy.
C: voltage responses (top) generated by current injection from + 0.4 to
-1 nA at an interval of -0.1 nA (bottom) recorded from a stellate neuron in
layer II. Note the depolarizing voltage sag in response to hyperpolarizing
current pulses.
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mEC layer II neurons were visually identified using infrared video microscopy
(Olympus BX51W1) and differential interference contrast optics. About 70% of the
neurons in layer II of the mEC are stellate neurons (Klink and Alonso, 1997). A
schematic illustration of the EC appears in Figure 27.
15T

Stellate neurons are the most numerous class of excitatory neurons in layer II.
These neurons are usually located in layer II or the border of layer II and III, and they
have distinct “star like” morphology with a larger and polygonal soma and a variable
number of main dendrites radiating out from the cell body but are devoid of a clearly
dominant dendrite (Deng and Lei, 2007) (Figure 27) These neurons have unique
electrophysiological properties; i.e., hyperpolarizing current pulse injection always
caused the membrane potential to attain an early peak and then “sag” to a steady-state
level (Alonso and Klink, 1993, Deng and Lei, 2007).
CRF Augments HCN-Channel Currents in Layer II Stellate Neurons
Because we initially found that I h recorded by whole-cell configuration
R

R

underwent significant run-down, we used perforated-patch recordings (Figure 28). Cells
were held at -50 mV and a series of hyperpolarizing voltages (from -50 mV to -130 mV
at an interval of 10 mV) were applied for 1 s to record the voltage-current relationship
before and after the application of CRF (Figure 28A). A single voltage step (from -50 mV
to -130 mV) was applied every 20 s to measure the time course of I h in response to CRF
R

R

application (Figure 28 C). At the end of experiments, ZD 7288 (100 µM) was applied to
corroborate the identity of the recorded I h (Figure 28). Under these circumstances, bath
R

R

application of CRF (0.1 µM) significantly increased I h (133±8% of control, n=9,
R

R

p=0.002, Figure 28 B) demonstrating that CRF up-regulates I h .
R
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R

Figure 28.

CRF enhances I h recorded from layer II stellate neurons in perforatedpatch recordings.
A: I h recorded by hyperpolarizing to different voltages from the holding
potential of -50 mV for 1 s at an interval of 10 mV before (left) and after
(middle) application of CRF. Application of ZD 7288 (100 µM) at the end
of the experiments blocked I h .
B: Voltage-current relationship before and after the application of CRF. *
P<0.05, ** P<0.01.
C: Time course of I h recorded by hyperpolarizing from -50 mV to
-130 mV before, during and after the application of CRF. Application of
ZD 7288 at the end of the experiments completely blocked Ih. Inset shows
the current traces recorded at different time points indicated in the figure.
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We further determined the effects of CRF on the voltage-sensitivity of I h conductance. I h
R

R

R

conductance (G H ) was determined as the amplitude of I h measured at different potentials
R

R

R

R

(V) divided by the driving force (V-E H ), where E H is the reversal potential of I h . The
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value of E H was arbitrarily set at -35 mV, which represents the median E H reported in a
R

R

R

R

variety of cell types (Ghamari-Langroudi and Bourque, 2000). The G H at different
R

R

voltages were normalized to the maximal G H and plotted versus the voltages. The
R

R

voltage-conductance relationship was fit by the equation G H(V) = 1/(1+e-k(V-V1/2)), where
R

R

P

P

G H(V) is the fraction of maximal G H observed at individual voltage, k is the slope factor
R

R

R

R

and V 1/2 is the half-maximal voltage. CRF shifted the V 1/2 by 5.7±1.4 mV (n=9, P=0.004)
R

R

R

R

to a more depolarized potential (Figure 29 A). CRF slightly but significantly altered the
slope factor (k) (n=9, p=0.025, Figure 29 B).

Figure 29.

Effects of CRF on the voltage-sensitivity of I h. conductance
A: Voltage-conductance relationship before and after the application of
CRF.
B: Summarized V 1/2 (left) and k (right). The open symbols represent the
values for individual cells and the solid symbols indicate the averages.
CRF slhifted the V 1/2 to more depolarized potential and slightly, but
significantly altered the slope factor (k).
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We then tested the involvement of CRF 2 receptors in CRF-induced increases in
R

R

I h . Bath application of the selective CRF 2 antagonist, K41498 (0.1 µM), blocked CRFR

R

R

R

mediated augmentation of I h (n=5, P=0.2, Figure 30 A 1 -A 2 ) whereas application of the
R

R

R

selective.
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Involvement of cAMP Not PKA in CRF-Mediated
Increases in Ih in Layer II Stellate Neurons

Figure 30.

CRF augments I h via activation of CRF 2 receptors.
A 1 -A 2 : Application of CRF in the presence of CRF 2 antagonist, K41498,
failed to increase I h .
B 1 -B 2 : CRF did not enhance I h in slices cut from CRF 2 knockout mice.
C 1 -C 2 : Application of CRF increased I h in slices cut from wild-type mice.
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Furthermore, CRF did not increase I h in slices cut from CRF 2 knockout mice
R

R

R

R

(n=9 cells from 3 mice, P=0.27, Figure 30 B 1 -B 2 ) whereas CRF still significantly
R

R

R

R

increased Ih in slices cut from wild-type mice (n=7 cells from 3 mice, P=0.02, Figure 30
C 1 -C 2 ).
R

R

R

R
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CRF 1 antagonist, NBI 27914 (0.1 µM) still significantly augmented I h (n=9,
R

R

R

R

P=0.009, Figure 31 A 1 -A 2 ). These data together indicate that CRF increases I h via
R

R

R

R

R

R

activation of CRF 2 receptors.
R

Figure 31.

R

CRF 1 receptors are not involved in Ih increase.
A 1 -A 2 : Application of CRF in the presence of CRF 1 antagonist,
NBI27914, still augmented I h .
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We further probed the roles AC/cAMP/PKA pathway in CRF-induced increases
in Ih in layer II stellate neurons. CRF-induced increases in I h were blocked by application
R

R

R

R

of MDL 12330A (50 µM, 107±4% of control, n=7, p=0.15, Figure 32 A 1 -A 2 ) and
R

R

R

R

SQ 22536 (400 µM, 104±2% of control, n=5, P=0.14, Figure 32 B 1 -B 2 ) indicating that
R

R

R

R

CRF- mediated facilitation of I h requires the functions of AC and cAMP. However,
R

R

application of CRF still augmented I h in the presence of Rp-cAMPS (100 µM, 150±21%
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of control, n=6, P=0.008, Figure 32 C 1 -C 2 ) and KT 5720 (1 µM, 127±3% of control,
R

R

R

R

n=5, P=0.026, Figure 32 D 1 -D 2 ) demonstrating that CRF-induced increases in I h is
R

R

R

R

R

R

independent of PKA activity.

Figure 32.

CRF-induced enhancement of I h is mediated by cAMP but not by PKA.
A 1 -A 2 : Application of CRF in the presence of AC inhibitor,
MDL 12330A, failed to increase I h significantly.
B 1 -B 2 : CRF did not enhance I h in the presence of another AC inhibitor,
SQ 22536.
C 1 -C 2 : Application of CRF in the presence of Rp-cAMPS still increased
Ih .
D 1 -D 2 : Application of KT 5720, another PKA inhibitor, failed to block
CRF-induced increases in I h .
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CRF Increases AP Firing Frequency in Layer II Stellate Neurons of the EC
We then tested the effect of CRF on neuronal excitability by recording AP firing
from the layer II stellate neurons. Bath application of CRF (0.1 µM) for 7 min.
significantly increased the firing frequency of these neurons (control: 1.06 ± 0.16 Hz;
CRF: 3.69 ± 0.44 Hz; n = 7; P = 0.001; Figure 33), and the firing frequency was
sustained even during the wash, after the application of CRF was stopped.

Control
CRF
50 mV

Wash
5s

Figure 33.
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Bath application of CRF increased the firing frequency of APs recorded
from layer II stellate neurons in EC.
A 1 : APs recorded prior to, during, and after application of CRF (0.1 μM).
A 2 : time course of CRF-induced increases in AP firing frequency (n = 7).
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CRF Causes Increase in Inward HCs
We next examined the effects of CRF on the inward holding current, in voltageclamp mode, CRF induced an inward shift of the HCs recorded at −60 mV (−37.1 ± 3.1
pA; n = 9; P < 0.001; Figure ), further confirming the membrane depolarizing effect of
CRF.
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Figure 34.

CRF causes increase in inward HCs.
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CHAPTER IV
DISCUSSION
A number of brain regions including the hippocampus, the amygdala and the EC
are involved in the epileptogenesis. However, the cellular and molecular mechanisms are
still not well established. The EC is an important limbic structure involved in the
development, maintenance and spread of seizures in the patients with TLE and in
epileptic animal models (Spencer and Spencer, 1994, Gloveli et al., 1998, Avoli et al.,
2002, Avoli and de Curtis, 2011). Studies show that the EC is more susceptible to
seizures than the hippocampus. EC is a six-layered structure and functions as a gateway
to the hippocampus and other cortical regions (Witter et al., 1989, 2000). The current
study focuses on layers II and III for the following reasons: The layer III pyramidal
neurons are hyperactive in vivo after the induction of TLE, and thus play a critical role of
epileptogenesis. Layer III neurons are preferentially lost in both human TLE (Kim et al.,
1990, Du et al., 1993) as well as animal models of epilepsy (Du and Schwarcz, 1992, Du
et al., 1995). With the onset of epilepsy and loss of CA3 neurons and the SC pathway
(Ben-Ari and Cossart, 2000), the TA pathway has been suggested as a major excitatory
drive to the principal neurons of the CA1 region (Barbarosie et al., 2000, Avoli et al.,
2002, Wu and Leung, 2003). Thus altered pyramidal cell excitability in the layer III of
the EC is likely to have a greater impact in the development of TLE. The neurons of
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layer II are well spared and become hyperexcitable (Bear et al., 1996) due in part to a
reduction in inhibitory input (Kobayashi and Buckmaster, 2003), and proexcitatory
alterations in sodium channel gating parameters (Hargus et al., 2011).Thus layer II cause
an excitatory drive into the DG and the hippocampus (Buckmaster and Dudek, 1997)
resulting in seizure induction and propagation. Hence mEC layer II neurons can be a
potential site of action of AEDs to suppress neuronal excitability or to reduce the seizure
activity once fully evoked (Hosseinmardi et al., 2007).
A number of factors can precipitate seizures in patients with epilepsy (Spector et
al., 2000), and stress is amongst the most common triggering factors (Lai and Trimble,
1997, Frucht et al., 2000, Haut et al., 2003, Nakken et al., 2005, Haut et al., 2007,
Sperling et al., 2008). Epileptic patients show a dysregulation in the HPA axis (Zobel et
al., 2004, Mazarati et al., 2009) and increased basal levels of stress hormones, which
further increase after seizures (Abbott et al., 1980, Pritchard et al., 1985, Culebras et al.,
1987, Galimberti et al., 2005). CRF is a 41 amino acid neuropeptide initially isolated by
Vale and his colleagues (Vale et al., 1981), a hypothalamic factor which activates the
HPA axis, initiating the release of ACTH from the pituitary, which in turn causes the
release of glucocorticoids from the adrenal cortex, to regain homeostasis (Dunn and
Berridge, 1990). CRF mediates the endocrine, autonomic, and behavioral responses to
stress (Aldenhoff et al., 1983, Ehlers et al., 1983, Siggins et al., 1985, Swanson et al.,
1986, Conti and Foote, 1995, Sawchenko et al., 1996, Baram and Hatalski, 1998).
Supporting evidence from various studies using immunolabeling, radioimmunoassay, and
mRNA expression have demonstrated that CRF is widely distributed in brain areas of.,
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human (Charlton et al., 1987), rat (Fischman and Moldow, 1982), and mouse(Nakane et
al., 1986). In addition to the PVN of the hypothalamus, CRF-containing neurons are also
found in various other brain regions, and is highly expressed in areas associated with
developmental seizures, such as the hippocampus and the amygdala (Gray and
Bingaman, 1996, Yan et al., 1998);(Steckler and Holsboer, 1999). The extrahypothalamic source of CRF has been demonstrated by central administration of CRF
which caused anxiety-like behavioral and autonomic effects (Britton et al., 1982, Dunn
and File, 1987, Koob and Heinrichs, 1999) and these behaviors persisted in
hypophysectomized rats (Eaves et al., 1985). Abnormalities in the HPA- and the extraHPA axis-CRF homeostasis have been documented with epilepsy. CRF transduces its
0T

0T

effects via two B-type G-protein coupled receptors CRF 1 and CRF 2 , which show 70%
R

R

R

R

homology (Perrin and Vale, 1999). Free levels of CRF are maintained in the brain as well
as periphery by a binding protein called CRF-BP. Both the receptors and the binding
protein have distinct pharmacological profiles (De Souza, 1995, Gulyas et al., 1995,
Dautzenberg and Hauger, 2002, Chatzaki et al., 2006, Fekete and Zorrilla, 2007), and are
distinctly and differentially distributed throughout the brain (Steckler and Holsboer,
1999). Various animal models revealed that intracerebroventricular injection of CRF
induces seizures (Ehlers et al., 1983, Marrosu et al., 1987, Marrosu et al., 1988, Weiss et
al., 1993) and the levels of CRF and CRF-BP are increased in patients as well as animals
models of epilepsy.Despite of the tremendous amount of studies relating the EC and CRF
in mediating epilepsy, not much is known about the role and relevance of CRF in the EC.
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Based on the available information that CRF, CRFRs and CRF-BP mRNA was
shown in various regions including the EC, our overarching hypothesis of this project
was that CRF in the EC binds to its receptors and facilitates epilepsy. To begin to test this
hypothesis, we initially wanted to examine the presence of CRF and the type of receptors
in EC, using immunocytochemsitry and western blot techniques. While strong
immunoreactivities were detected for CRF and CRF 2, there was no detectable
R

R

immunoreactivity for CRF 1 . These results were further corroborated by westernblot. The
R

R

reported masses for CRF, CRF 2 and CRF 1 are, ~20 kDa (Lauber et al., 1984, Watabe et
R

R

R

R

al., 1991, Saoud and Wood, 1996) ,~63 kDa (Miyata et al., 1999) and 76–80 kDa
(Radulovic et al., 1998, Spiess et al., 1998) respectively. While bands closer to the above
respective molecular mass were observed for both CRF and CRF 2 , no conspicuous band
R

R

was observed for CRF 1 . These results demonstrated that both CRF protein and CRF 2
R

R

R

R

receptors are predominantly expressed in the EC (Kurada et al., 2014), as shown in

previous in situ hybridization studies (Lovenberg et al., 1995b), suggesting that CRF
plays an important role in the EC.
A number of studies have shown CRF to be a potent epileptogenic molecule and
CRF contributes to increased excitation in limbic regions. For example,
intracerebroventricular injections of CRF produces spontaneous seizures (Ehlers et al.,
1983, Weiss et al., 1986b, Marrosu et al., 1988, Baram and Schultz, 1991b). CRFinduced epileptiform activity is initiated in the amygdala which then spreads to other
brain regions (Baram et al., 1992). Since our previous results indicate the presence of
CRF and its receptor, we then wanted to explore whether CRF facilitates epileptiform
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activity in the EC. A number of in vitro and in vivo models of epilepsies have been
developed to study the mechanisms underlying different types of epilepsies. Various
chemical convulsants are commonly used such as, PTX, Pentylenetetrazol, pilocarpine
and kainic acid. These drugs generally act by interfering the normal synaptic transmission
(Kupferberg, 2001) .Here we used a well-established in vitro model called PTX-slice
seizure model. The PTX-induced seizure model resembles the simple partial and
generalized forms of human epilepsy (Fisher, 1989, Sierra-Paredes and Sierra-Marcuno,
1996, Sarkisian, 2001). PTX blocks the chloride channels linked to GABA A -receptors
R

R

and thereby prevents the conductance of chloride ions into the neuronal membrane. This
result in the inhibition of GABA neurotransmission and GABA mediated inhibition of
neuronal activity and thereby elicits seizures (Orhan et al., 2012). Using PTX (100 µM)
in the acsf, epileptiform activity was induced. Extracellular field recordings were
obtained from layer III of the EC, in the horizontal hippocampus-entorhinal slices After
stable events, basal or control epileptiform activity was recorded and then CRF (0.1 µM)
was applied. Electrophysiological measurements showed that application of CRF to the
entorhinal slices robustly increased the frequency of epileptiform activity induced by
PTX. The CRF-mediated epileptiform activity was sustained even during wash, after the
application of CRF (Kurada et al., 2014), indicating that CRF is triggering a cascade of
signaling events resulting in possible receptor and/or channel up regulation. Our results
demonstrate that the EC is at least one of the action sites for CRF-mediated facilitation of
epilepsy.

87

The above experiments were conducted in the horizontal slices containing the EC,
hippocampus and other cortices. Although it was unlikely that the connections among the
EC and other regions to be complete after cutting the slices, it might be possible that the
action site of CRF could likely be in the other brain regions other than the EC. In order to
confirm whether the action site is the EC, we recorded from the ‘mini’ slices in which
other brain regions except the mEC were cut off. CRF still induced the same level of
facilitation of PTX-induced epileptiform activity (Kurada et al., 2014). These results
together demonstrate that CRF acting in the EC can facilitate epileptiform activity. Since
CRF-mediated increase in epileptiform activity recorded from the horizontal and the
mini-slice was statistically indistinguishable, horizontal slices were used for the rest of
experiments, for the sake of convenience. The calculated EC 50 was 19.6 nM. However,
R

R

since the maximal effect was obtained at 0.1 µM, the same concentration was used for the
rest of our experiments.
CRF is known to show pro-convulsant properties. CRF could not elicit seizures
by itself in infant hippocampus rats (Hollrigel et al., 1998), when CRF is administered
before amygdala kindling, the time to reach the fully kindled state is markedly reduced
(Weiss et al., 1986) The proconvulsive role of CRF is further confirmed by studies from
the Lewis rats, with reduced CRF expression. These rats take longer to kindle and require
more electrical stimulations (Weiss et al., 1993). Based on these studies, we then wanted
to test whether CRF by itself can induce epileptiform activity in the EC. In the absence of
PTX, when CRF was bath applied, CRF could not induce any epileptiform activity.
However, in the presence of sub-threshold concentration (10 µM) instead of (100 µM)
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PTX, though the sub-threshold concentration of PTX could not elicit any epileptiform
activity, application of CRF could produce epileptiform events. These results are in
agreement with the previous studies showing the pro-convulsant actions of CRF in other
brain regions. These results corroborate the fact that CRF cannot induce epileptiform
activity but itself in the EC, but can increase the epileptiform activity induced by PTX.
Our next question was regarding the mechanisms by which CRF modulates
epilepsy. We next wanted to determine the type of receptor, CRF 1 and/or CRF 2, involved
R

R

R

R

in CRF-mediated facilitation of epileptiform activity in the EC. Since our earlier
experiments showed strong immunoreactivity for CRF 2 , which was further confirmed by
R

R

the western blot, we pretreated slices with antagonists for CRF 2 receptors. In the
R

R

presence of CRF 2 antagonists, CRF-mediated facilitation of epileptiform activity was
R

R

significantly blocked. Multiple antagonists were used to rule out any possibility of
antagonist non-specificity. The results obtained from the above pharmacological
challenges were further corroborated by CRF 2 KO mice. When CRF was applied to the
R

R

slices cut from the CRF 2 KO mice, CRF failed to increase the frequency of epileptiform
R

R

activity. However, CRF still exerted robust facilitatory effects on the frequency of
epileptiform activity when applied to slices cut from WT mice. Though the above results
suggest that CRF 2 is predominantly expressed in the EC and facilitates the epileptiform
R

R

activity, it might be possible that CRF 1 receptors were undetected by the methods we
R

R

employed in our experiments, but may still be functionally active. To rule out this
possibility, we tested the role of CRF 1 in CRF-mediated epileptiform activity. In the
R

R

presence of CRF 1 antagonists, CRF could still significantly augment the frequency of
R

R
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PTX-induced epileptiform events. Furthermore, CRF binds with high affinity to the
CRF 1 but has low affinity for CRF 2 (Dautzenberg and Hauger 2002). Hence it might be
R

R

R

R

possible that CRF 1 receptors, even if present in the EC, might be non-functional. Our
R

R

results have therefore filled a gap for the effects of CRF in the EC by demonstrating that
CRF-elicited facilitation of epileptiform activity is mediated by CRF 2 receptors.
R

R

The next question was the role of endogenously released CRF in facilitating
epileptiform activity in the EC. CRF is released within many other brain regions such as
the hippocampus, the amygdala (Roozendaal et al., 2002) locus ceruleus (Valentino and
Wehby, 1988, Snyder et al., 2012). Since CRF can travel to distances longer from the
regions of origin, within the brain (Bittencourt and Sawchenko, 2000a), it might be
possible that CRF from extra-entorhinal source which is transported from the distal brain,
here in this case, the hippocampus and other regions in the horizontal slice, and acts on
CRFRs in the EC. The levels of free CRF in the extracellular component are regulated by
the CRF-BP. We then determined the role of endogenously released CRF by the
application of the CRF-BP antagonist CRF6-33, which also increased the frequency of
PTX-induced epileptiform activity suggesting that endogenously released CRF is
involved in epileptogenesis. Thus, the CRF-BP may hold as a reservoir of CRF and
therefore the regulation of the interaction between CRF and CRF-BP may represent a
mechanism by which CRF can be released to activate the CRF receptors present in the
EC. Taken together these results demonstrate that the CRF endogenously released from
the EC facilitates epileptiform activity via activation of the CRF 2 receptors.
R
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What are the signaling mechanisms by which CRF facilitates epileptiform activity
in the EC? The biological actions of CRF are likely to be mediated by CRFRs and their
intracellular signals. Both CRF 1 and CRF 2 are primarily coupled to G s proteins,
R

R

R

R

R

R

activating the AC/cAMP/PKAcascade (Dautzenberg and Hauger, 2002, Grammatopoulos
and Chrousos, 2002, Hauger et al., 2006). CRFRs also have various degrees of coupling
competence and potency to interact with other G-protein systems including G q , G i , G o ,
R

R

R

R

R

R

G i1/2 , and G z (Grammatopoulos et al., 2001). Thus CRF can modulate various signaling
R

R

R

R

cascades and kinases comprising of protein kinase B (PKB), protein kinase C (PKC),
mitogen-activated protein (MAP) kinases and intracellular Ca2+ concentrations in a
P

P

tissue-specific and concentration dependent manner (Dautzenberg and Hauger, 2002,
Grammatopoulos and Chrousos, 2002, Hauger et al., 2006).The AC/cAMP/PKA pathway
is predominant Gs activated signaling cascade, increasing the neuronal firing. However,
whether PKA is coupled with the CRF in transducing the epileptiform activity is not
clear. Elucidating the signal transduction mechanism in the EC, will help in better
understanding of the etiology of the disease. To elucidate the signaling mechanisms,
various activators and inhibitors of the cAMP/PKA signaling cascade were used. In order
to overcome the problem of non-specificities of the inhibitors used in the blockade of the
signaling cascade, we took care of the following parameters: i). Used more than one type
of the inhibitor ii). Carefully chose the effective concentrations and IC 50 values of the
R

R

inhibitors given in the literature. iii).To ensure pharamacological effectivesness, we pretreated the slices with the inhibitors as described in the literature prior to the application
of CRF. Activation of CRF 2 receptors increases the function of AC resulting in
R

R
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augmentation of cAMP production and subsequent activation of PKA. We demonstrate
that AC and cAMP are fully required but PKA may be partially necessary for CRFmediated facilitation of epileptiform activity based on the following results. AC is an
enzyme that converts ATP to cAMP. Hence inhibition of AC should result in blockade of
CRF-mediated increases in epileptiform activity. To test this, we used AC inhibitors,
MDL 12330A and SQ 22536. In the presence of these AC inhibitors, CRF-induced
augmentation of epileptiform activity was completely blocked. Next, elevation of
endogenous cAMP level should augment epileptiform activity by itself. To test this, we
used Forskolin, a cAMP activator and IBMX, a PDE inhibitor. PDE is the enzyme that
degrades cAMP to 5’-AMP and thereby limits the stimulatory effect of the cAMP
cascade. By inhibiting PDE using IBMX, the levels of cAMP are therefore increased.
Forskolin and IBMX produced significant increases in epileptiform activity by
themselves and thus mimic the effects produced by CRF. If PKA is involved in CRFmediated increases in epileptiform activity, blocking PKA should block the CRFmediated effects. To test this hypothesis, PKA was inhibited by KT 5720 and
Rp-cAMPS. This resulted in significantly reduced but not completely blocked CRFmediated increases in epileptiform activity. In accordance with our results, tremendous
evidence demonstrates that AC/cAMP/PKA pathway plays a facilitatory role in epilepsy
(Boulton et al., 1993, Yechikhov et al., 2001, Higashima et al., 2002, Vazquez-Lopez et
al., 2005, Ure and Altrup, 2006, Ristori et al., 2008).
Given the direct link among ion channel activity, neuronal excitability and
epilepsy, ion channels remain an active area of investigation. What are the ion channels
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that are involved in CRF-mediated increases in epileptiform activity? Since HCN
channels play an important role in epilepsy (Huang et al., 2009, Noam et al., 2011) and
the entorhinal neurons express robust HCN-channels (van der Linden and Lopes da Silva,
1998, Dickson et al., 2000), we tested the roles of HCN-channels in CRF-mediated
facilitation of epileptiform-activity. HCN channels maintain the RMP and thus control
the neuronal excitability. HCN channels are regulated by neurotransmitters and hormones
that act via cAMP, cGMP, or intracellular Ca2+(Pape 1996); cAMP and cGMP modulate
P

P

HCN channel activity via direct interaction with the cyclic nucleotide-binding domain
protein of the C-terminus (Ludwig et al. 1998). HCN channels interact with multiple
neurotransmitter systems and are coupled both positively, via the Gs, and negatively, via
Gi-proteins, to the cAMP synthesis and thus are up- and down-regulated (Frere and Luthi
2004; Pape 1996). Since our results show the involvement of cAMP in CRF-mediated
epileptiform activity, and HCN channels are modulated by cAMP; and the layer II stellate
neurons express high levels of HCN channels, we wanted to test the role of these
channels in CRF-mediated facilitation of epilepsy. We then probed the role of HCNchannels. HCN-channels by themselves exert three effects on picrotoxin-induced
epileptiform activity. First, application of the selective HCN-channel blocker ZD 7288
significantly reduced the frequency of the epileptiform activity suggesting that HCNchannels modulate the rhythm of epilepsy. This is also consistent with the roles of HCNchannels because HCN-channels are involved in rhythmic modulation of neuronal
activity. Second, inhibition of HCN-channels results in enhanced number of
synchronizing events in single epileptiform activity. Third, HCN-channel inhibition also
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enhanced the duration of individual epileptiform activity. It must be noted that the
synchronizing events represent the interictal activity, which is a state of continuous
neuronal excitability; the above results show that CRF modulates the HCN channel
properties.
If CRF plays a role in modulating the HCN channels, CRF should modulate the
current flowing through these channels as well. HCN channels carry current known as Ih.
We then wanted to probe the role of I h current in CRF-mediated facilitation of
R

R

epileptiform activity. Perforated patch clamp recordings were performed from the layer II
stellate neurons. Voltage-current relationship revealed that CRF augments Ih. These
results were further corroborated by the blockade of HCN channels using ZD7288.
Furthermore, CRF increased the conductance and caused membrane depolarization which
is indicative of increased neuronal excitability. In order to identify whether CRF
modulates the Ih current via CRFRs, using selective CRF 2 inhibitors, we found that CRF
R

R

augments I h current via CRF 2 receptors. These results were further corroborated using
R

R

R

R

CRF 2 KO mice, in which CRF-mediated I h increase was blocked. In the presence of
R

R

R

R

AC/cAMP blockers, CRF could not facilitate the increases in I h , whereas the PKA
R

R

inhibitors have no effect on CRF-mediated I h increase. This shows that CRF augments I h
R

R

R

via cAMP signaling, but PKAis not required. The result that blockade of HCN-channels
by ZD 7288 also blocked CRF-mediated increase in the frequency of epileptiform
activity suggests that HCN channels contribute to CRF-mediated augmentation of
epileptiform activity. However, we do not consider HCN channels as the sole player in
CRF-mediated facilitation of epileptiform activity based on the following pieces of
94
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evidence. First, the number of the synchronizing events in single epileptiform activity
after inhibition of HCN-channels by ZD 7288 was still significantly increased after
application of CRF. Second, the duration of individual epileptiform activity was still
enhanced by CRF after inhibition of HCN channels by ZD 7288. Third, our results
suggest that CRF facilitates I h via cAMP without requirement of PKA. If HCN channels
R

R

are the only performer, inhibition of PKA should not exert any effects on CRF-mediated
facilitation of epileptiform activity. However, our results demonstrated that inhibition of
PKA significantly reduced CRF-mediated enhancement of epileptiform- activity
suggesting that molecules other than HCN channels are still targets of CRF. Further
studies will identify other mechanisms underlying CRF-induced facilitation of
epileptiform activity.
CRF is known to induce excitability in cortex and the forebrain (Eberly et al.
1983), the hippocampus, Purkinje cells, and the dorsal vagal complex is augmented by
CRF-mediated reductions in afterhyperpolarization (AHP) (Aldenhoff et al. 1983;
Hollrigel et al. 1998; Lewis et al. 2002; Yamashita et al. 1991).We then wanted to probe
the role of CRF at the cellular level and the mechanisms involved. When CRF (0.1 µM)
was applied to the stellate neurons, a significant increase of neuronal firing was produced
in the presence of CRF and was sustained even when CRF was washed out. Also, CRF
produced significant inward holding currents, which could be due to opening of Na+/ClP

P

P

/K+ channels These results indicate that CRF acts at the neuronal level and increases
P

P

P

excitability. Further experiments to identify the ion channels and signaling mechanisms
would help to better understand the role of CRF in the EC.
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Summary and Significance
CRF is an important neuropeptide and involved in various brain functions, and a
potent epileptogenic neuropeptide. The seizure-facilitating effects of CRF have largely
been explained based on its actions in various other regions of the brain such as the
hippocampus and the amygdala. However, the action sites and mechanism of actions of
CRF are not yet determined. CRF and CRFR immunoreactivity was found in the EC, but
the role and relevance of CRF in facilitating seizures are not well established. This
dissertation provides evidence that CRF facilitates epileptiform activity via activation of
CRF 2 receptors. and cAMP signaling, whereas PKA is partially involved. Endogenously
R

R

released CRF is responsible for the CRF-mediated epileptiform activity, as blockade of
CRF-BP by a selective antagonist, CRF6-33, significantly increased the epileptiform
activity. CRF-mediated facilitation of epileptiform activity involved the modulation of
HCN channels and increases in I h current activated via CRF 2 signaling, with the
R

R

R

R

involvement of cAMP. PKA was not involved in the enhancement of CRF mediated
increases in I h (Figure 35). Further understanding the mechanisms of pro-convulsant
R

R

effects of CRF within the EC, will provide valuable information for developing targeted
drug moieties that can reduce the seizure activity.
Accumulating evidence suggests that the stress-related hormone CRF and the
HPA axis play a critical role in the pathophysiology of TLE. CRF facilitates exacerbation
of neuronal excitability by modulating molecular, structural and synaptic functions
resulting in decreased seizure threshold and epilepsy. Epilepsy-mediated by stress
system, especially by CRF and its receptors have important implications for the therapy
96

of patients with TLE. Changes in the molecular composition and function of the CRF
system and its receptors may alter the modulatory effects of CRF in facilitating epilepsy
in various brain regions. A deeper understanding of the mechanisms and specific target
regulation of CRF receptor in regionally distinct roles of the CRF receptors in various
brain regions would allow specific target receptors in the epileptic neurons and thus
increasing efficacy and reducing the side effects. Furthermore, certain neuropeptide
characteristics such as discrete neuroanatomical localization, relatively little disruption of
normal physiology by the neuropeptide ligands, and the requirement of higher stimulation
frequencies for the neuronal release of neuropeptides than those required by monoamine
neurotransmitters and GABA colocalized in the same neuron makes CRF an alluring
target for epilepsy treatment. Thus, pharmacological alteration of CRF function might
normalize pathological activity in circuits mediating stress, such as the HPA axis, without
producing unwanted side-effects (Hokfelt et al., 2000)(Hokfelt et al. 2000). Indeed, drugs
that are antagonists at CRF receptors might have a particularly low side-effect burden
because such compounds would not be expected to disrupt normal physiology in the
absence of neuropeptide release. CRF-receptor antagonists have been shown to increase
seizure threshold and are effective in animal models of febrile seizures (Toth et al. 1998).
This information implies that selective blockers of CRF-receptor activation might be
useful anticonvulsants for some types of seizures, which with further investigation might
be useful to treat other epilepsy types. However, CRF system affects a wide range of
behaviors and physiological processes. Added to these, the complexity of the signaling
mechanisms makes it much more complicated to successfully target the CRF-system for
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pharmacotherapy. Most importantly, CRF-mediated TLE animal data requires further
validation in human tissue to provide us new important information about the role of CRF
in TLE. Further insights into the complex role of CRF system in the facilitation and
exacerbation of epilepsy would help us identify new molecular targets for novel AEDs,
which might help inhibit and/or abrogate the disease pathogenesis.
Additionally, CRF-mediated facilitation of I h current in the EC might be an
R

R

important mechanism underlying the generation of high-frequency activity in the
hyperexcitable EC and could become an alternative target for defining antiepileptic
treatment strategies. In summary, we report that CRF has profound excitatory effects on
neuronal excitability in the layer II stellate neurons leading to increases in I h current and
R

R

thus facilitating the epileptiform activity. A potential mechanism for this enhanced
excitatory effect could be the increase in the I h current. Since the EC is involved in the
R

R

initiation and maintenance of seizures, this study provides a rationale for selective
targeting of the CRF 2 receptors, through receptor antagonist as a new treatment strategy
R

R

for the TLE
Future Directions
Since drug delivery systems for therapy cannot target individual brain regions and
cross talk between various peptide and neurotransmitter systems makes it much more
difficult for single target drug therapies (Arzt and Holsboer, 2006), a deeper
understanding of signal transduction pathways mediated by CRF system is quintessential
for specific targeting to obtain greatest therapeutic benefits. Focusing on the downstream
effects of CRF would help unravel the critical mechanisms underlying the facilitation of
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CRF-meditated epilepsy not only in the EC, but other brain regions as well. Further
experimentation with intracellular recordings is required to identify other kind of ligandvoltage gated ion channels involved in the CRF-mediated, cAMP/PKA-dependent
modulation of epileptiform activity and increases in neuronal excitability.
Since our results show that CRF causes membrane depolarization, which could be due
1T

to the activation of cationic conductance or inhibiting background K+ channels or both,
1T7

P

P

leading to neuronal excitability. Firstly, if CRF-induced depolarization is due to the
activation of cationic conductance, influx of extracellular Na+ should be the major ions
P

P

responsible for the membrane depolarization. This will be tested by replacement of
extracellular NaCl with the same concentration of NMDG-Cl. Then test whether Ca2+ is
P

P

involved, by substituting extracellular Ca2+ with the same concentration of Mg2+ and
P

P

P

P

including 1 mM EGTA to chelate the ambient Ca2+. Blockade of CRF-induced inward
P

P

HC due to the above challenges suggests the role of specific cationic channel. If
background K+ channels are involved, CRF induced currents should have a reversal
17T

P

P

potential close to the K+ reversal potential. We will measure the reverse potential using a
P

P

ramp protocol (from −120 mV to 0 mV) to construct the voltage–current curve before and
during the application of CRF (0.1 μM).Under these conditions, if CRF induces a current
with a reversal potential close to that of theoretical K+ reversal potential calculated by the
P

P

Nernst equation, it suggests that CRF produces membrane depolarization by inhibiting
background K+ conductance. Using the classic K+ channel blockers tetraethylammonium
P

P

1T

P

P

1T

(TEA), 4-aminopyridine (4-AP) or Cesium (Cs+), the properties of K+ channels involved
1T
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P

P

1T

in CRF-induced depolarization would then be characterized, based on the different kinds
of K+ channels.
P

P
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Figure 35.

Summary and Future Directions

CRF has been shown to have diverse effects on synaptic transmission, resulting in
neuronal excitability and epileptogenesis (Hollrigel et al., 1998). Using whole-cell
recording techniques, the actions of CRF on synaptic transmission would be identified.
To investigate the actions of CRF on glutamate-mediated synaptic transmission in the
EC, spontaneous –miniature and evoked-monosyaptic excitatory post synaptic currents
would be recorded from the layer-II stellate neurons. To investigate the actions of CRF
on GABA-mediated synaptic transmission, spontaneous inhibitory post synaptic currents
will be recorded from the layer-II stellate neurons.
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Since our results show that CRF enhances I h , using surface-protein biotinylation
R

R

method, we will identify whether HCN channels are upregulated in the EC. EC shows
HCN1 and HCN2 type predominantly. Using specific antibodies for these channels, we
will identify whether there is CRF is involved in modulation of HCN surface channel
expression in the EC.
Limitations of the study:
The in vitro model of epilepsy used in the current study have several advantages
such as, ease of application of various concentrations of drugs, relatively intact local
circuits of the tissue to visualize and obtain stable intracellular recordings from the layerII stellate neurons without any anesthetics or immobilizing agents. These features helped
to draw important conclusions regarding the role and relevance of CRF and its receptors
as well as elucidate some of the molecular mechanisms involved in facilitation of
epileptiform activity in the EC. However, the study has certain limitations when
extrapolating the results. One of the major limitations is that the in vitro slice
preparations lack intact functioning circuits of a normal brain, and are thus isolated from
influences of other hormones, neurotransmitters or neuropeptides. Thus the results may
differ from intact organism and need to be replicated in vivo, e.g., using CRFR transgenic
mice to further elucidate the mechanisms underlying CRF-mediated facilitation of
epilepsy in the EC, with further confirmation by human studies. Despite the major
limitations, the in vitro slice models of epilepsy have been proven to be very useful as
adjunctive approach to other models of epilepsy, due to the challenges involved in human
studies.
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ABBREVIATIONS

aCSF

Artificial cerebral spinal fluid

ACTH

adrenocorticotropic hormone.

AEDs

Anti-epileptic drugs

ANOVA

Analysis of variance

ATP

Adenosine triphosphate

BSA

Bovine serum albumin

CA3

Cornu Ammonis

CaCl 2

Calcium Chloride

cAMP

cyclic Adenosine 3’:5’-cyclic monophosphate

CNS

Central Nervous System

CO 2

Carbon dioxide

CRF

Corticotropin Releasing Factor

CRH

Corticotropin Releasing Hormone

CRF 1

Corticotropin Releasing Factor receptor 1

CRF 2

Corticotropin Releasing Factor receptor 2

DMSO

Dimenthyl sulfoxide

DG

Dentate gyrus

EDTA

Ethyelenediaminetetracetic acid

R

R

R

R
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EGTA

Ethyleneglycoltetraacetic acid

EC

Entorhinal cortex.

FBS

Fetal bovine serum

GABA

gamma-Aminobutyric acid

HEPES

2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, buffer

HPA

Hypthalamic-pituitary-adrenal axis

HRP

Horseradish peroxidase

KCl

Potassium Chloride

KO

Knockout

MgCl 2

Magnesium Chloride

mEC

medial-Entorhinal Cortex

NaCl

Sodium Chloride

R

NaHCO 3

Sodium bicarbonate

NaH 2 PO 4

Sodium dihyrdogen phosphate

NMDA

N-Methyl-D-aspartic acid

O2

Oxygen

PBS

Phosphate buffer saline

PIP 2

Phosphatidylinositol 4,5-bisphosphate

PKA

Protein Kinase A

PKB

Protein Kinase B

PKC

Protein Kinase C

PVN

Paraventricular nucleus

R

R

R

R

R

R
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PTX

Picrotoxin

PVDF

Polyvinylidene fluoride

RMP

Resting Membrane Potential

SDS-Page

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

SD

Standard Deviation

SEM

Standard error of mean

TBS-T

Tris buffered saline containing Tween 20

TA

Temporoammonic

TEMED

N,N,N’,N’-tetramethylene-diamine

TLE

Temporal lobe epilepsy

UV

Ultraviolet

WT

Wild-type
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